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Abstract. Magnetic nanoparticles have proven to be promising 
theranostic agents, namely tools for therapy and diagnosis. Among 
them, superparamagnetic iron oxide nanoparticles (SPIONs) highlight 
for their biocompatibility and reduced toxicity. Here, we describe the 
synthesis and characterization of SPIONs by co-precipitation of ferric 
and ferrous salts under mild conditions. These particles were able to 
accumulate in inflamed areas fact that was increased upon the 
application of an external magnetic field. Resonance magnetic 
imaging studies have shown their suitability as negative contrast 
agents for diagnosis. In addition, hybrid nanoparticles were obtained 
by incorporating the above described SPIONs into liposomes or 
nanoemulsions. The findings have confirmed the high potential of 
these systems for biomedical applications.              
 
Introduction 
       
      The impact of nanotechnology is strongly associated to the development of 
nanomaterials and nanoparticles (NPs) [1,2]. In particular, magnetic 
nanoparticles (MNs) present a number of advantages if compared to other  
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nanosystems. Their magnetic properties can be exploited for the targeting of 
drugs and as contrast agents. The duality that involves both therapy and 
diagnosis, all in one, or theranostic effect [3] has gained interest in the 
biomedical field, becoming an encouraging approach towards a personalized 
medicine. For that purpose, the design of nanosystems often requires the 
combination of one or several modifications of traditional NPs. It usually 
involves changes in their surface or their incorporation into other NPs 
conferring in this way also versatile, multifunctional, biocompatible and 
biodegradable properties [4,5]. 
 There is a great variety of materials that show magnetism in some extent 
depending on their atomic structure and temperature. The compounds with 
stable magnetic properties are classified into two main groups: ferromagnets, 
with permanent magnetism, and paramagnets, with magnetism that appears 
upon the application of an external magnetic field [6]. On the other hand, the 
size is a decisive aspect concerning to the functionality of the MNs.                     
A ferromagnet of macroscopic size contains numerous regions called 
magnetic domains in the demagnetized state. Within each domain all the 
atomic moments (represented as arrows in Fig 1) are aligned in one of the 
directions leading to spontaneous magnetization.  
   The direction of the magnetization, however, varies from domain to 
domain so as to minimize the magnetostatic energy. On a purely statistical 
basis, all available easy directions will be used equally in the material. 
Hence the particle as a whole will only show a net magnetization when 
submitted to an applied field [7]. A ferromagnet below a certain critical 
diameter (DCR) shows a single domain. Further reduction in size results in a 
superparamagnetic (DSPM) behavior meaning that magnetic properties are 
only present upon the application of an external magnetic field.   
 Among the several types of MNs, up to now, iron oxide nanoparticles 
(IONs) have proven to be the most promising MNs for theranostic 
applications mainly for their high imaging sensitivity, therapeutic efficacy, 
inherent biocompatibility and low cost [8]. This group comprises different 
chemical combinations of iron such as ferrites with a general formula 
MFe2O4 (M= Co, Ni, Zn, Mn), magnetite (Fe3O4), maghemite (γ-Fe2O3) or 
the non-stoichiometric mixture of the last two, with diameters comprised 
between 1 and 100 nm. This array of sizes supposes an additional advantage 
in the design of IONs with different magnetic behavior and consequently for 
a variety of applications. Therefore, below a certain diameter, DSPM, they are 
superparamagnetic being magnetized only in presence of a magnetic field. 
Superparamagnetic IONs (SPIONs) can be directed by an external magnet 
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towards a given target zone (Figure 2). Then, the application of a magnetic 
field moves the SPIONs toward the magnet and concentrates near its 
location. SPIONs revert to a non-magnetic state upon removal of the 
external magnet [9].  
 The application of a high-frequency alternating magnetic field can 
selectively heat SPIONs resulting in a hyperthermia effect that can be 
exploited for drug targeting. Therefore, their responsiveness to a magnetic 
field makes these particles suitable stimuli-sensitive systems as they can 
change their physical properties in response to an external stimulus and, in 
case of carrying drugs, these can be selectively delivered to the target site, 
minimizing any side effects [10]. 
 The magnetic properties SPIONs make them suitable candidates for 
molecular imaging (MI), a diagnostic approach that combines molecular 
biology and in vivo imaging performed in real time with the possibility of 
sequential and longitudinal monitoring. MI has the advantage over other 
diagnostic tools that allows high soft tissue contrast, spatial resolution and 
penetration depth for what it is considered one of the most powerful 
noninvasive imaging techniques in diagnostic [11,12,13]. In particular, 




Figure 2. Procedure for magnetically-guided drug targeting of nanoparticles. The 
enhanced permeability and retention effect facilitates the extravasation of the nanoparticles 
from the pores in leaky tumor blood vessel walls [6]. 
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resonance imaging (MRI) [14,15]. SPIONs improved the contrast-to-noise 
ratio in MRI by shortening the spin-spin T2 relaxation times of the water 
protons within the tissues or regions of interest, enhancing in this way the 
image contrast. 
 The versatility and functionality of SPIONs can be enhanced by 
modifications of their surface consisting mainly on coating the surface 
with ligands or by their inclusion into other nanoparticles giving hybrid 
nanosystems such as liposomes or nanoemulsions [16,17]. The 
combination of liposomes and SPIONs results in multifunctional 
magnetoliposomes (MLs) or all in one system that can also incorporate a 
variety of molecules. The first reference on MLs is found in a 1989 
publication by Kiwada [18]. These MLs had a size in the micrometer 
range, far too big for biological applications. From then, several 
procedures have been described resulting in nanometer-sized MLs [19,20]. 
Figure 3 shows a prototype of multifunctional or hybrid liposome (large 
unilamellar liposome, LUV), composed of phospholipids, with theranostic 
properties. Thus, encapsulated SPIONs in the inner core or embedded into 
the lipid bilayer provide a tool for magnetic targeting; the presence of                     




Figure 3. Prototype of a multifunctional large unilamellar magnetoliposome with the 
associated properties provided by each component. PEG: Polyethylene glycol;                       
RGD: Arginine (R)-Glycine (G)-Aspartic acid (D); Rho-B: Lissamine Rhodamine B 
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for biological targeting; drugs located depending on their hydrophilic or 
hydrophobic character as SPIONs in the aqueous compartment or among 
the lipid acyl-chains, respectively, make the systems appropriate for 
chemotherapy. On another hand, the presence of polymers (e.g. 
polyethylene glycol, PEG) on the outer leaflet of the vesicles, protect them 
from the opsonization and rapid uptake from the bloodstream once 
administered. Finally, fluorescent probes can be incorporated to the lipid 
bilayer for detection purposes. 
 Similarly, the incorporation of SPIONs into oil-in-water nanoemulsions 
results in magnetic nanoemulsions (MNEs). MNEs can include the same 
components as mentioned for liposomes and are particularly interesting as drug 
delivery systems of hydrophobic drugs. Both, MNEs and MLs are biodegradable 
and show low toxicity [22]. 
 
1. Synthesis and characterization of iron oxide nanoparticles 
 
 SPIONs were synthesized according to the method described by                       
Berger et al. [22]. Briefly, a mixture of Fe (OH)2 and Fe (OH)3 was obtained 




 in presence of strong alkali 
and under vigorous stirring. Subsequent fast aging of those hydroxides 
generates magnetite. The overall reaction is: 
 





 In order to provide colloidal stability to the particles and prevent their 
aggregation, they are usually coated with other nanoscale materials, resulting 
in the so named ferrofluids. Hydrophilic polymers such as dextran and its  
 























 1 Hydrodynamic diameter measured by dynamic light scattering 
 2 Polydispersity index. Its value varies from 0 for a monodisperse sample to 1 for a      
    polydisperse population. 
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derivatives, polyethylene glycol (PEG), chitosan (CHI) and alginate (ALG) 
are among the most used for the stabilization of naked magnetic 
nanoparticles [23]. We have studied the influence of the initial amount of 
CHI, ALG and PEG of different molecular weights in the stabilization of the 
magnetite. The optimal concentration of polymer needed for coating the NPs 
was calculated through adsorption isotherms and the amount coated was 
measured by thermogravimetry. 
 The ferrofluids were also characterized by measuring their size and size 
distribution by dynamic light scattering (DLS) and charge (  potential) with 
a Zetasizer Nano ZS90 (Malvern Instruments, UK). High-resolution TEM               
(HR-TEM, 2010F Jeol Microscope, Japan) indicated that the particle 
diameter was around 11 nm, value that was confirmed by X ray diffraction 
(XRD). Some of the above results are illustrated in Table 1 and Figure 4. 
 The magnetic properties of the ferrofluids under the influence of a magnetic 
field were measured with a superconducting quantum interference device 
(SQUID) magnetometer (Quantum design MPMS XL, San Diego, California, 
USA) at room temperature. All samples showed superparamagnetism without 
magnetic hysteresis at room temperature.  
 




 A lipid or lipid mixture of interest in chloroform/methanol (2:1, v/v) 
was introduced into a round bottom flask and the organic solvent was 
evaporated in a rotavapor under reduced pressure until the formation of a 
thin film. The dried mixture was then hydrated with an aqueous suspension 
of hydrophilic magnetic particles. In the case of hydrophobic SPIONs and 
hydrophobic drugs as indomethacin, they were added to the organic 
mixture and proceed as mentioned before. Up to now, the samples consist 
on a heterogeneous population of MLs. In order to obtain homogeneous 
samples, MLs were sonicated in an ultrasonic processor (Hielscher, 
Teltow, Germany) or submitted to extrusion cycles through a 200 nm 
polycarbonate filters (Extrude device, Avestin, Ottawa, Canada).                 
Ligand-targeted MLs with the arginine-glycine-aspartic acid motif (RGD) 
were also designed to study their ability to interact with cancer cells [24]. 
MLs were characterized as mentioned for SPIONs and additionally, the 
amount of lipid, encapsulated drug and SPIONs were measured as 
described in [9]. The average size of MLs was around 200 nm with low 
polydispersity (< 0.2). 
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2.2. Magnetic nanoemulsions 
 
 The advantage of MNEs over MLs is their higher loading capacity of 
hydrophobic materials. Oil in water MNEs were prepared by mixing olive 
oil, cholesterol (CHOL) and the phospholipids 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE-PEG) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) dissolved in organic solvent. Hydrophobic 
SPIONs and indomethacin were also added to the organic phase. Then, the 
organic solvent was removed by rotary evaporation at 35 
o
C and the dried 
mixture was hydrated with water or buffered saline solution. The resulting 
crude emulsion was homogenized by spontaneous emulsification (low 
energy) or ultrasonication with an UP200 St ultrasonic processor 
(Hielscher, Teltow, Germany) (high energy) (Figure 5) [26,27]. NEs were 
characterized as described for MLs.  
 For internalization studies in cells, MLs and MNEs were labeled with 
the fluorescent probe 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rho-PE). In both 





Figure 5. Schematic representation of the magnetic NEs loading indomethacin and 
SPIONs obtained by high energy method (ultrasounds) or low energy method 
(spontaneous emulsification). On top components of the NEs [27]. 
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3. Magnetoliposomes accumulate in inflamed sites 
 
 The ability of MLs to reach inflamed areas was studied in a first 
assay by administering intravenously bare MLs to mice, namely MLs 
containing only phospholipids with encapsulated SPIONs [25]. 
Previously, sterile air pouches were produced by injecting air 
subcutaneously into the back of the mice. Then, animals were divided in 
four groups. In two of them, acute inflammation was induced by 
injecting 1.2 % carrageenan (phologen) to the pouch (inflammation 
groups). The injection in the other two groups (control groups) consisted 
on sterile saline. MLs were then injected i.v. to one of the two 
inflammation (I + MLs), and control groups (C + MLs). Mice were 
sacrificed 20 min after the injection.  
 The iron content in exudates (pouch), plasma and organs was 
analyzed by inductively coupled plasma atomic emission spectroscopy 
(ICP-AES, Perkin Elmer Optima 3200RL, Massachusetts, USA). Iron 
levels were higher in animals with inflammation that in control animals. 
After the administration of MLs to the control group, iron content 
increased similarly to the measured for animals with inflammation and 
MLs. There was no change in the concentration of iron in the liver after 
i.v. administration, whereas there was an increase in the spleen compared 
to the control group (Figure 6).  
 Iron biodistribution indicated that MLs accumulated mainly in the 
inflammation zone without the need of an external magnet to                      
potentiate the migration of MLs to the target site. A possible explanation 
to this fact is the enhanced permeability and retention effect as a 
consequence of the leaky vasculature of the tumor or in inflamed areas 
that allows the intratumoral accumulation of particles smaller than                 
200 nm [28]. 
 In a later study [9], a similar experiment was performed in which an 
external magnetic field induced a selective biodistribution of bare MLs to 
the inflamed area (Figure 7).  
 By this magnetically guided drug targeting approach, MLs 
accumulated at the site of inflammation (exudates) and simultaneously 
were removed from the blood. In addition, their content decreased in the 
liver and spleen. The increase in iron levels in exudates depended on the 
time of exposure of the external magnetic field (Table 2).  
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Figure 7. Experimental device to measure the effect of an external magnetic field on the 
biodistribution of MLs (left) after i.v. injection into mice (right). An inflammatory focus 
was introduced on their backs. Two ND2Fe12B disk magnets (25 x 10 mm, of 600 mT per 
side were place over the hole in the Plexiglas cages [9]. 
  





C 0.04 ± 0.04 4.04± 1.02 621±310 665±180 
I 0.26 ± 0.13 4.01± 1.27 712±224 836±278 
IN 0.33 ± 0.11 4.12± 1.07 873±99 1,446±390 
INM 0.56 ± 0.12 2.89± 0.42 674±64 1,264±35 
 
C: control, mice with back air pouch receiving sterile saline; I: inflammation control                    
group, animals with carrageenan-induced inflammation in the air pouch receiving 
saline; IN: as I but receiving MLs i.v; and INM as IN but under the effect of a magnet 
located just above the inflammatory pouch for 20 min (Figure 7) [9]. 
 
 TEM micrograph of the exudates showed the presence of intact MLs 20 min 
after the injection. This is a consequence of the size of the SPIONs (~ 12 nm) 
that is too large to passively cross the phospholipid bilayer. Iron release is only 
possible after the action of opsonins and cells of the mononuclear phagocyte 
system or other destabilizing agents. 
 
4. Ligand-targeted Magnetoliposomes 
 
 It is described that nanoparticles can be directed to a target site by 
functionalization of the external core. Insertion of peptides is one of the most 
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successful strategies [29]. For instance, the cyclic RGD peptide, bounded to the 
outer leaflet of the liposomal bilayer thorough a lipid-PEG-maleimido group, can 
bind vascular endothelial cells at inflammation sites [30]. Dubey et al. [31] 
indicated that cyclic RGD peptide anchored sterically stabilized liposomes 
bearing 5-FU were significantly more active against primary tumor and 
metastasis than the non-targeted sterically stabilized liposomes and free drug. 
Therefore cyclic RGD peptide anchored sterically stabilized liposomes hold 
potential of targeted cancer chemotherapeutics. Based on this premise, we 
designed an experiment aimed to study the targeting of RGD-MLs to integrin 
αVβ3 expressed in many cancer cells as the Hela cellular line. Bare MLs and 




Figure 8. Magnetoliposomes, MLs, composed of phosphatidylcholine (PC)/cholesterol 
(CHOL) (8:2 mol/mol) synthesized for internalization studies in Hela and 3T3 cells.    
PEG-MLs: pegilated MLs (long circulating) and RGD-MLs: functionalized MLs 
(biological targeting). The images correspond to confocal observations (Leika TCS-SP2, 
Heidelberg, Germany) after the incubation of MLs with Hela cells for 4 h. MLs were 
labeled with rhodamine-PE (red), the nucleus with membrane-permeable dye Hoeschst 
33342 (blue) and the cell membrane with cell membrane-impermeable Alexa Fluor                
488-conjugated wheat germ agglutinin (green). 
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 Previously to the cellular internalization studies, the cytotoxicity of 
naked SPIONs and MLs was analyzed in Hela and 3T3 (control) cellular 
lines by two typical assays, MTT that measures the metabolic activity in the 
mitochondria of viable cells and NR that gives information about the 
membrane integrity. MLs were viable at the concentrations studied [24]. 
 Unexpectedly, confocal microscopy and flow cytometry showed that 
bare MLs were internalized in higher extent than the MLs displaying the 
targeting moiety [24]. Apparently, cellular uptake of ligand-targeted MLs 
was inhibited by the PEG chains of the surface. To overcome this drawback, 
MLs surface should display PEG chains of different length, short to prevent 
the adsorption of proteins on the surface of the proteins and a long chain to 
favor the interaction with the cellular receptor.  
 
5. Magnetoliposomes as contrast agents for Magnetic 
Resonance Imaging 
 
 Agar phantoms with MLs or SPIONs were prepared to avoid particle 
aggregation during the application of the magnetic field. Then MRI 
measurements were performed on a 7.0 T BioSpec 70/30 horizontal animal 
scanner (Bruker BioSpin, Ettlingen, Germany). T1 (positive contrast) and T2 
(negative contrast) relaxometry maps as well as the relaxation rates r1 (1/T1) 
and r2 (1/T2) were obtained as described in [14]. The relaxivity for a MRI 
contrast agent calculated from equation 1 is described as the increase of the 
relaxation rate of the water (solvent) induced by 1 mmol.L
-1
 of the active 





 where i refers to 1 (r1) or 2 (r2), and CCA, to the iron concentration of the 
contrast agent (SPIONs). 
 Table 3 shows the relaxivity values for the SPIONs alone and incorporated 
into liposomes of different composition. r1 is poorly sensitive to SPIONs at 7 T 
due to the reduced susceptibility to dipolar contributions at high field, in addition 
to the presence of bulky surface groups hindering the surface accessibility of 
water to the magnetic cores. Contrarily, r2 values are bigger because transversal 
relaxivities are highly sensitive to the presence of substances around the 
magnetic core.   
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Table 3. r1, r2 and r2/r1 ratio of magnetic hydrophobic (O) and hydrophilic (H) 











O 0.96 74.5      78 
H 0.80 50.7     63 
O-DMPC 0.90 340    378 
H-DMPC 9.10 1282   140 
O-DMPC-CHOL 0.80 230   288 
O-DMPC-PS 0.80 798  1000 
O-DOPC 0.90 630  700 
H-DOPC 3.40 678  199 
O-DOPC-PS 0.90 995  1000 
 
 
      DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn- 
      glycero-3-phosphocholine; CHOL: cholesterol; PS: phosphatidylserine. 
 
 MLs composed of saturated (DMPC) or unsaturated phospholipids (DOPC), 
with or without CHOL or PS (negatively charged phospholipid) showed higher 
transverse reaction rates r2 compared to the values obtained for SPIONs alone as 
a consequence of the reduction of the diffusion coefficient of water near the 
nanoparticles. The coating of SPIONs with lipid bilayers provided a longer 
interaction between the water protons and the magnetic field at the surface of the 
magnetic core than in absence of coating. 
  
6. Magnetic nanoemulsions are suitable vehicles for 
hydrophobic drugs 
 
 NEs were chosen for their high payload, fact that favors the loading of large 
amounts of drugs. Therefore, multifunctional MNEs were prepared 
encapsulating indomethacin and SPIONs. Cytotoxicity studies were performed 
as described for MLs in Hela and 3T3 cellular lines. Then, the anti-inflammatory 
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activity of indomethacin loaded into MNEs, compared to the effect of free drug, 
was studied in a carrageenan-induced paw edema in rat model [26]. The height 
of the paw edema was measured at different times. Therefore, the study was 
performed with three groups of animals: A) carrageenan; B) carrageenan and 
indomethacin and, C) carrageenan and MNEs loaded with indomethacin. The 
peak of the edema was observed at 4 h for group A), and 6 h for the remaining 
two. The analysis of the area below the curve (Figure 9), with the                    
Turkey-Kramer statistical test, indicated the lack of differences between groups 
A and B or B and C, while significant differences (p<0.05) were noticed 




Figure 9. Top: viability of Hela and 3T3 cells after the incubation with magnetic-NEs for 
24 h. Bottom left: changes in paw edema induced by carrageenan in rats at different times, 
after administration of saline (control), free indomethacin (IND) (2mg kg-1) or 
indomethacin loaded MNEs (Nanoemulsion). Bottom right: area under the curve of the 
paw increase obtained from the data of the previous figure [26]. 
 
 Ulcers in the stomachs were observed only in the group that was 
administered with free drug, thus confirming protective role of the NEs in 
reducing the drug side effects. 
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7. Conclusion 
 
 Stable aqueous suspensions of superparamagnetic iron oxide nanoparticles 
stabilized with polyethylene glycol, chitosan or alginate (ferrofluids) were 
successfully prepared by a co-precipitation method under mild conditions. Their 
incorporation into liposomes gave also stable systems that showed ability to 
accumulate in inflamed areas, fact that increased upon the application of an 
external magnetic field. Magnetoliposomes presented enhanced negative 
transversal relaxivity (r2) compared to SPIONs, fact that indicates their 
suitability as negative contrast agents for magnetic resonance imaging. On 
another hand, magnetic nanoemulsions showed to be good vehicles for 
indomethacin with reduced side effects in comparison with the administration of 
the free drug. In summary, MLs and MNEs are good candidates as nanosystems 
for magnetic resonance imaging, for delivering hydrophobic drugs and can 
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Abstract. Probiotic Escherichia coli Nissle 1917 (EcN) is a good 
colonizer of the human gut and its efficacy in the inflammatory 
process undergone in ulcerative colitis has been demonstrated. The 
probiotic action is mainly through the modulation of intestinal 
epithelial tight junctions and immune system. Here we review the role 
of outer membrane vesicles (OMVs) released by this probiotic strain 
on the modulation of intestinal homeostasis.  EcN OMVs enter into 
host epithelial cells via clathrin-mediated endocytosis and are sorted to 
lysosomes via endocytic compartments. In cellular models of 
intestinal barrier, EcN OMVs stimulate the underlying immune 
system through the intestinal epithelium, triggering immune and 
defense responses. Thus, the use of probiotic derived OMVs could be 
a safe probiotic-derived strategy targeting intestinal inflammatory 
processes.              
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Introduction 
       
      In the mammalian gut, bacteria are not in direct contact with the 
epithelium due to the mucin layer that covers the intestinal mucosa. In fact, a 
compact inner mucin layer, which is impenetrable to bacteria, physically 
separates microbiota and host epithelial cells. Thus, the crosstalk between 
microbiota and the host mainly relies on secreted factors that can go through 
the mucus layer, reach the epithelium and activate cell signalling pathways 
that modulate host immune and defence responses such as secretion of 
cytokines or antimicrobial peptides, mucus production or regulation of 
intercellular intestinal junctions [1,2]. Bacterial secreted factors can be 
released into the extracellular milieu as free-soluble compounds or included 
in membrane vesicles.  
 All bacteria, either commensal or pathogenic strains, have evolved 
different systems to contact and communicate with host cells. One strategy is 
the formation of membrane vesicles that can deliver the cargo to distant 
targets in the host. In fact, membrane vesicles are considered intercellular 
communicasomes. 
 Here we give a view of the intestinal microbiota and especially in the 
vesicles released by Gram-negative bacteria, which are known as outer 
membrane vesicles (OMVs). We review the modulation of the intestinal 
barrier and the immune response provided by membrane vesicles secreted by 
the gram-negative probiotic Escherichia coli Nissle 1917. 
  
1. Gut microbiota 
 
 The mammalian intestine is one of the most densely colonized 
ecosystems. The whole of the microorganisms that inhabit the intestine 
constitute the so-called intestinal microbiota, which is formed by between 
500 and 1000 microbial species, mostly anaerobic and anaerobic facultative 
bacteria. Human gut microbiota constitutes a biomass of 1.5 kg shaped by 
10
14
 microorganisms [3], thus outnumbering the total host cells by an 
estimated 10-fold. The microbiota has an enormous metabolic capacity and 
carries a repertory of genes that exceeds by more than 100 times the genetic 
information of the host. The concentration and the variety of microorganisms 
increase throughout the gastrointestinal tract, being the colon the most 
densely colonized section [4]. 
 Gut microbiota plays important roles that are crucial for the function of 
the intestine and host survival. Therefore, it has been considered as an organ 
that acts synergistically with the host [5]. In this context, microbiota 
plays metabolic functions mainly associated with energy recovery, synthesis 
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of vitamins and fermentation of non-digestible compounds, which 
metabolism produces short chain fatty acids that have a positive influence on 
the differentiation and proliferation of the intestinal epithelium. Gut 
microbiota also provide important protective functions related with 
displacement of pathogens, either by competing for nutrients and specific 
receptors, or through expression of anti-microbial factors. Finally, gut 
microbiota has relevant structural functions that control the integrity of the 
intestinal barrier and it is essential for the development and normal function 
of the host immune system [6]. 
 
2. Gut microbiota-host communication 
 
 The communication between the microbiota and the host occurs at the 
intestinal mucosa, which is complex and structured in three components: the 
mucus layer, the epithelial cell barrier and the intestinal immune system. 
 The mucus layer that covers the gastrointestinal tract is organized in two 
layers at the colon level. The inner layer (50-200 μm thick) is firmly attached 
to the epithelium and consists of a compact structure formed by stacked 
mucin polymers in which bacteria cannot penetrate. The outer mucus layer is 
looser and is the habitat for commensal bacteria.  
 Epithelial cells that form a monolayer that separates the external 
environment from the host internal medium constitute the second layer of 
defence. This epithelium is mainly formed by enterocyte-type cells, which 
are the absorptive cells, and by other specialized cell types such as goblet 
cells, responsible for mucus secretion. M cells detect bacteria that have 
surpassed the internal mucus layer, phagocyte and translocate them to the 
lamina propria where a local immune response is triggered in order to 
eliminate the microorganism or induce tolerance. Paneth cells are specialized 
epithelial cells that secrete peptides with antimicrobial activity. This layer of 
epithelial cells constitutes a dynamic physical barrier. Adjacent cells in the 
monolayer are interconnected by different types of intercellular junctions; of 
special interest are the tight junctions (TJ), which regulate the permeability 
of the intestine helping to maintain a strict and regulated separation between 
the organism and the intestinal lumen. In addition, the intestinal epithelial 
cells must signal to the underlying immune system in response to luminal 
bacteria.  
 The third component of the intestinal mucosa is the immune system 
formed by the lymphoid tissue associated to the intestine. Specifically, the 
immune cells of the lamina propria coordinate the development of innate and 
adaptive responses that allow a state of tolerance to food antigens and 
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commensal microbiota and trigger specific mechanisms to eradicate 
pathogens [7]. 
 The interaction between the microbiota, the intestinal epithelium and the 
host immune system is essential for host homeostasis. Changes in microbiota 
population can have harmful impact on human health. Many factors 
(infections, genetics, environment, diet, reduced physical activity) may lead 
to imbalances or shifts in microbiota composition, a concept known as 
dysbiosis. This condition has been linked to gastrointestinal disorders caused 
by bacterial or viral infections, and also to metabolic (obesity, insulin 
resistance, hepatic steatosis) and immunological diseases (allergies, 
autoimmune diseases or inflammatory diseases) [8,9].  
 
3. Probiotics in gut homeostasis 
 
 The administration of probiotics is one of the approaches in the 
treatment of intestinal disorders, especially those associated with microbiota 
imbalance and homeostasis alteration. These approaches are aimed to restore 
the initial equilibrium and to regain the integrity of the intestinal barrier and 
the health status of the individual.  
 Probiotics are defined as “live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host” (WHO and FAO 
2006). To be considered a probiotic, the strain should not have human 
pathogenic effects, be able to survive during the intestinal transit, be a good 
colonizer of the gut mucosa, diminish pathogen adherence to cell surface and 
invasion, and display antimicrobial properties against pathogens. Besides all 
these characteristics, the probiotic must be accompanied by beneficial effects 
on the host at different levels such as on the intestinal barrier function, 
intestinal immune system and on the microbiota itself [8]. Concerning 
intestinal barrier function, the action can be directed to several targets. One 
mechanism is the strengthening of the epithelial barrier through the 
regulation of the expression of TJ proteins or their redistribution inside the 
cell. Other mechanisms are related with the expression of molecules that 
interfere with pathogens such as adhesins that allow adhesion of the 
probiotic to intestinal mucosa diminishing pathogen adhesion by competitive 
exclusion, or secreting anti-microbial peptides that inhibit pathogen growth 
or survival. A probiotic may also modulate the host immune system.  
 However, it is important to note that not all these properties are found in 
all probiotics. Thus, each probiotic has individual mechanisms of action, 
which differ from those of other strains and confer its specific 
characteristics. This explains why a probiotic strain is useful to treat a 
specific pathology but not others. However, it has been proposed that some 
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mechanisms could be highly widespread among the probiotic genera while 
others are strain-specific. 
 Most of the widely used probiotics are Gram-positive bacteria from the 
genus Lactibacillus or Bifidobacterium. Besides, the Gram-negative strain 
Escherichia coli Nissle 1917 (EcN) is a well-studied probiotic used in the 
treatment of intestinal diseases. 
 
3.1. Escherichia coli Nissle 1917 (EcN) 
 
 This Gram-negative bacterium belongs to the Enterobacteriacea family 
and is included in the E. coli B2 phylogenetic subgroup. This strain was 
isolated by Alfred Nissle in 1917 from the stool of a soldier who survived a 
shigellosis outbreak during the First World War. It is currently 
commercialized as a probiotic for the treatment of dysbiosis and intestinal 
inflammatory bowel diseases in Germany with the trade name of Mutaflor® 
and in Italy as EcN®. The use of this probiotic has been particularly 
recommended for the prevention of diarrheal diseases caused by pathogens 
such as Shigella, Salmonella or E. coli, and for the treatment of ulcerative 
colitis. In fact, various clinical trials have proved its therapeutic benefits in 
inducing and maintaining remission of this inflammatory disease [10].  
 A number of studies have been carried out to characterize the properties 
of EcN, both at the phenotypic and genetic levels. This probiotic is a good 
colonizer of the human gut and positively affects gastrointestinal 
homeostasis and microbiota balance, as it promotes anti-inflammatory 
modulation of the immune response and reinforces the function of epithelial 
barrier through the positive regulation and redistribution of the TJ proteins. 
EcN has GRAS status (generally recognized as safe). Several factors 
contribute to its safety, such as the expression of a semi-rough 
lipopolysaccharide (LPS) with shortened O6 side chains that confers this 
probiotic sensitivity to serum. This probiotic does not produce known toxins, 
but several adhesins and fimbriae that allow this probiotic to effectively 
compete with pathogens for the binding sites in the host intestine. The EcN 
genome has been sequenced (genome size 5,441,200 bp) and is estimated to 
contain 5,324 coding sequences, being about 108 genes strain-specific 
[11,12]. Comparative genomic analyses indicate that EcN arises from of an 
uropathogenic ancestor like E. coli strain CFT073 and that through 
evolutionary processes has lost virulence factors and gained genes that 
confer to this strain the probiotic properties [13]. In this context, EcN 
expresses a wide repertoire of fitness factors that promote its 
competitiveness, a fact that can probably explain its success as a probiotic.  
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 Within the fitness factors there are microcins, iron uptake systems, 
adhesins and proteases that help intestinal colonization [14,15]. EcN encodes 
six different iron transport systems that are advantageous for competing with 
other intestinal bacteria for the acquisition of iron within the gastrointestinal 
tract, in which this metal is limiting. In addition, this probiotic strain 
expresses several adhesins such as FimA, F1C and curli that help biofilm 
formation and contribute to EcN adhesion to intestinal mucosa and, 
therefore, the colonization and persistence in the intestinal tract [16]. 
 Regarding the immunomodulatory effects, EcN modulates the host 
immune system by promoting a decrease in proinflammatory cytokines IL-2, 
TNF-α, IFNγ and an increase in anti-inflammatory cytokines like IL-10. This 
probiotic can reduce intestinal inflammation by downregulating expansion of 
newly recruited T cells into the intestinal mucosa. In this situation, resident 
activated intestinal T cells allow elimination of deleterious antigens, and 
hence contribute to maintaining immunological homeostasis [17]. On the 
other hand, the structural protein of the EcN flagellum, flagellin H1, is 
recognized by the immune receptor Toll-like receptor-5 (TLR5) on the 
epithelial host cell membrane. This interaction activates the downstream 
signaling pathway that triggers secretion of interleukin (IL) -8 (IL-8), a 
relevant cytokine that acts as a chemoattractant of neutrophils, ensuring the 
phagocytosis of pathogens in situ. Flagellin H1 also activates the host 
defense response to counteract adhesion and invasion of pathogens by 
increasing the synthesis of the inducible antimicrobial peptide β-defensin-2 
(hBD-2) [18]. This antimicrobial peptide has a large spectrum of action 
being active against Gram-negative and Gram-positive bacteria, yeasts and 
virus. Additionally, EcN expresses on its cell surface a capsular 
polysaccharide, named K5 antigen, typical of pathogenic E. coli strains of 
the urinary tract and other strains causing extraintestinal infections. This 
capsule mediates the interaction of EcN with enterocytes and induces the 
expression of various chemokines such as the monocyte chemoattractant 
protein-1 (MCP-1), CCL5 (or RANTES) that recruits T cells, eosinophils 
and basophils, the macrophage inflammatory proteins 2-alpha and 2-beta 
(MIP- 2α and MIP-2β) and interferon-γ (IFN-γ). The loss of this capsular 
polysaccharide drastically reduces the level of chemokine induction after 
interaction with the host [19]. 
 Within the modulatory effects, this probiotic is able to improve the 
intestinal epithelial barrier by strengthening TJs between adjacent epithelial 
cells. In vivo and in vitro studies have revealed that EcN promotes increased 
expression of the zonula occludens (ZO)-1 and ZO-2 proteins [20,21], 
although the microbial factors mediating these effects are not still known. 
More recently, it has been described that EcN mediates positive regulation of 
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the TJ protein claudin-14, and this effect has been attributed to the secreted 
TcpC protein [22]. 
 The probiotic effect of EcN has been attributed to the combination of 
several properties that include particular fitness factors, interference factors 
and immunomodulatory properties [23]. However, despite the successful 
therapeutic applications of EcN the bacterial effectors and molecular 
mechanisms responsible for its beneficial effects are not always well-known.  
 
4. Bacterial vesicles in host-microbiota cross-talk 
 
 OMVs are spherical membranous structures with an average diameter 
between 20 to 300 nm in size, which bud and detach from the cell during 
active growth. They contain a big range of bacterial molecules and 
compounds such as LPS, outer membrane proteins, periplasmic and 
cytosolic proteins, virulence factors, DNA, RNA and lipids. Thus, unlike 
other secretion systems, OMVs allow transfer of a diverse range of 
biochemically active molecules to proximal cells in a protected form. In the 
mammalian gut, OMVs are able to diffuse through the mucin layer, reach the 
intestinal epithelium and modulate its function and also control the innate 
and adaptive immune responses [24,25,26,27].  
 OMVs are released during all stages of bacterial growth in numerous 
media and conditions including natural environments such host fluids and 
tissues. They are originated from the outer membrane bacterial envelope, 
whose architecture is basic to understand vesicle biogenesis. The envelope of 
Gram-negative bacteria is formed by two membranes, the outer membrane 
and the cytoplasmic membrane, separated by the periplasmic space. These 
structures contain proteins that have key roles, such as nutrient acquisition, 
bacterial adhesion, secretion, signalling and protection against the external 
environment [28]. The mechanisms that lead to OMVs biogenesis are still 
poorly understood, although it is known that multiple processes seem to be 
involved, being destabilization of the membrane integrity a crucial factor 
[29]. All models proposed for OMVs biogenesis depend on an initial 
decoupling of the outer membrane from the peptidoglycan (PG) layer by 
disruption of the crosslinks between PG and the lipoproteins Pal and Lpp. 
This promotes the curvature of the outer membrane, leading to vesicle 
formation. Vesiculation can be also altered by factors such as temperature, 
nutrient availability, oxidation, quorum sensing and antibiotics [28].  During 
biogenesis, OMVs acquire a vast number of compounds, which are 
important for bacterial survival and for the interaction with the host [27]. 
However, the pathways by which OMVs include their cargo remain 
unknown [28,30].  
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 Many studies carried out with Gram-negative pathogens showed that 
OMVs are internalized into host cells and contribute to virulence by 
delivering cytotoxic factors and mediators that interfere with the immune 
system [24,31,32]. Nowadays, microbiota-derived vesicles are seen as key 
players in signaling processes in the intestinal mucosa [33,34]. However, 
studies in this field are still limited, being the first reports focused on 
Bacteroides fragilis [35,36], a main Gram-negative group in the 
gastrointestinal tract of mammals. OMVs from this commensal promote 
immunomodulatory effects and ameliorate colitis in mouse models. The 
beneficial effects are in part mediated by the capsular polysaccharide A 
(PSA) through TLR-2, although in dendritic cells OMVs from this 
microbiota strain trigger changes in gene expression that are PSA-
independent. Other studies reported the ability of Akkermansia muciniphila 
OMVs to protect the progression of induced colitis in mice [37]. Regarding 
Gram-positive bacteria, studies performed with Bifidobacterium bifidum 
LMG13195 showed that membrane vesicles from this probiotic activate 
the maturation of dendritic cells, triggering a regulatory T cells response 
[38]. 
 
5. OMVs released by the probiotic EcN modulate intestinal 
immune and defense responses 
  
 In the field of microbiota-derived vesicles, studies have been focused 
on OVMs released by the probiotic strain EcN and by commensal E. coli 
strains. Bacterial OMVs are isolated from culture supernatants and 
examined by transmission electron microscopy after negative staining  
(Fig. 1A). 
 
5.1.  Proteome of EcN OMVs  
 
 We approached proteomic analysis to identify the protein content of 
EcN OMVs [39]. This study was the first report of the vesicular proteome 
of a probiotic strain. By means of 1D SDS–PAGE and highly sensitive                 
LC–MS/MS analysis, 192 EcN vesicular proteins were identified with high 
confidence in three independent experiments. In general, the identified 
proteins provide functions related with bacterial survival and interaction 
with the host, similarly to other bacterial vesicles [40]. Interestingly, of the 
192 proteins, 18 were encoded by strain-linked genes and around 21% had 
not been previously described in bacterial vesicles. The EcN specific 
proteins are involved in the adhesion to the host tissues (fimbriae), immune 
modulation or bacterial survival in host niches (proteases, iron uptake 
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systems). Thus, these proteins may facilitate the colonization of the human 
gut. For instance, the presence of components of multiple iron uptake 
systems in EcN OMVs may allow the probiotic strain to outgrow 
commensal bacteria and compete with pathogenic strains that use similar 
siderophores for iron uptake. Concerning the identified proteases Pic and 
Sat, these proteins are typically associated to pathogens. Although the 
specific role in the probiotic strain has not been elucidated, it seems that 
they may act as fitness factors rather than virulence factors [41]. In this 
sense, Pic has been shown to promote intestinal colonization, 
hypersecretion of mucus and modulation of the host immune response 
[42]. 
 In addition to the strain-related proteins, other identified proteins may 
contribute to the beneficial effects of this probiotic. These are proteins also 
found in OMVs isolated from Gram-negative pathogens (57 common 
proteins out of 192 total identified proteins). These common proteins may 
allow bacterial establishment and persistence in host tissues, which is an 
essential issue for the activity of both probiotic and pathogens. This common 
protein group contains fitness factors that allow bacterial survival in the host, 
including periplasmic proteins that help nutrient sensing  (transport systems 
for amino acids, carbohydrates or inorganic ions), antimicrobial enzymes to 
kill competing bacteria (murein hydrolases), surface proteins that promote 
adhesion to host tissues, and factors able to modulate the host immune 
response (FlgE and FlgK). Interestingly, this common group is mainly 
formed by cytoplasmic proteins, most of them metabolic enzymes. They are 
moonlighting proteins that, depending on the cell location, can play different 
roles. Thus, in addition to the metabolic role, the secreted proteins play a 
function that contributes to gut colonization or modulation of the host 
immune response. A well-studied moonlighting protein is glyceraldehyde-3-
phosphate dehydrogenase [43,44,45,46].    
 Regarding the proteins identified for the first time in bacterial vesicles, 
the in silico functional analysis revealed that they may also contribute to 
OMVs functions that are essential in the context of this probiotic strain. An 
example is the porin NanC, whose expression is induced by                                   
N-acetylneuraminic acid, one of the most abundant sialic acids on the 
eukaryote cell membrane. The ability to use sialic acids as carbon and 
nitrogen sources may help EcN to colonize and persist in the intestinal tract.  
 This proteomic study [39] revealed that EcN OMVs are equipped with a 
wide variety of proteins related with adhesion, immune modulation and 
bacterial survival in host niches. Therefore, these proteins may contribute to 
vesicle targeting to particular host tissues and mediate the probiotic 
beneficial effects on intestinal function.  
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5.2. Internalization of EcN OMVs by intestinal epithelial cells  
 
 Uptake of OMVs by epithelial host cells is mainly mediated by 
endocytosis. The endocytic pathway depends on the composition and cargo 
of the vesicles. The two main pathways involved in OMVs internalization 
are clathrin-mediated endocytosis and lipid raft-dependent endocytosis. 
These pathways create endosomal compartments with different surfaces 
that allow the delivery of vesicle components to various subcellular 
destinations.  
 Many studies dealing with internalization of bacterial OMVs have 
been carried out with vesicles from Gram-negative pathogens. However, 
regarding microbiota or probiotic-derived OMVs, contribution to this field 
is restricted to studies performed with the probiotic EcN [47]. In this study 
EcN OMVs were labelled with rhodamine isothiocyanate B-R18. 
Fluorescence of this fluorochrome is quenched when inserted in bilayer 
membranes at high concentration, but when vesicles are fused with the 
host cell, the fluorescence is emitted and can be monitored using a 
microplate fluorescence reader. In this case, the intensity of fluorescence 
emitted is proportional to the amount of internalized vesicles. Following 
this experimental approach, kinetics studies performed in several intestinal 
epithelial cells (Caco-2, HT-29, HT-29-MTX) incubated with rhodamine 
B-R18-labeled OMVs showed a time-dependent increase in fluorescence, 
consistent with internalization of EcN OMVs. The presence of intracellular 
vesicles was confirmed by confocal fluorescence microscopy (Fig. 1B).  
 











Figure 1. A) Image of EcN OMVs visualized by electron microscope after 
negative staining. B) Visualization of internalized EcN OMVs in HT-29 epithelial 
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Figure 1. A) Image of Ec  s visualized by electron microscope after negative 
staining. B) Visualizat on of internalized EcN OMVs in HT-29 epithelial cells by 
fluorescence microscopy. Cell membrane was stained in gre n and nuclei in blue. 
Internalized rhodamine B-R-18 labeled OMVs were visualized in red. (Images have 
been provided by Alexandra Cañas). 
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 Experiments performed in the presence of specific endocytosis 
inhibitors allowed the identification of the pathway responsible for the 
uptake of EcN OMVs. The inhibitors tested were the cholesterol-
sequestering drugs nystatin and filipin III that disrupt lipid rafts, and 
chlorpromazine that inhibit clathrin-mediated endocytosis. OMVs entry 
was inhibited by chlorpromazine but not by nystatin or filipin III. 
Therefore, EcN OMVs are internalized by intestinal epithelial cells via 
clathrin-mediated endocytosis. It is well known that vesicles internalized 
through this pathway are sorted to lysosomal compartments. Accordingly, 
co-localization of EcN OMVs with clathrin and specific markers of 
endosomes and lysosomes was confirmed by confocal fluorescence 
microscopy [47]. No detection of OMVs in nuclei or mitochondria was 
observed, thus EcN vesicles are likely degraded inside lysosomes. In the 
acidic endo-lysosomal compartments some specific proteins or factors are 
dissociated from the vesicles and targeted to other subcellular locations to 
trigger specific actions and cell responses [48]. Although for EcN OMVs, 
the specific function and intracellular trafficking of vesicle-derived factors 
to other organelles have not been studied so far, flow cytometry analysis of 
phosphorylated γH2AX in the nucleus of cells incubated with EcN OMVs 
showed that components released from internalized vesicles promote 
double strand breaks in the cell DNA. This effect on DNA was also 
confirmed by the formation of DNA tails in the Comet assay. The               
vesicle-associated factor responsible for this genotoxic activity has not 
been identified. Interestingly, the probiotic EcN produces colibacin, a  
non-ribosomal peptide-polyketide that induces double strand breaks in 
DNA. This peptide is synthesized by enzyme activities encoded in the pks 
island. Studies performed with an EcN mutant deficient in colibactin 
synthesis showed that, besides its genotoxic activity, colibactin is required 
for the in vivo anti-inflammatory effects of this probiotic [49]. Although 
the mechanism by which colibactin is delivered into the host cell remains 
unknown, the effects triggered by EcN OMVs on DNA suggest that 
colibactin could be delivered to mammalian cells by OMVs.  
 Despite EcN OMVs promote double strand breaks on the cell DNA, 
these vesicles do not reduce cell viability nor cause oxidative damage [47].  
 
5.3.  EcN OMVs reinforce the intestinal epithelial barrier 
 
 The intestinal epithelial layer forms a physical and biochemical barrier 
that maintains the segregation between host and intestinal microbiota. The 
function and integrity of this epithelial barrier depend on several factors, 
including the production of a mucin layer that covers the epithelial surface 
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and avoids the intimate contact with intestinal microbes, the secretion of 
antimicrobial peptides, and the formation of TJs that seal the paracellular 
space between adjacent epithelial cells. In addition, intestinal epithelial 
cells are essential to integrate microbial signals and coordinate the immune 
cell responses.  
 Recent studies have shown the ability of OMVs released by the 
probiotic EcN to reinforce the intestinal epithelial barrier by modulating 
the expression of genes encoding proteins relevant for the barrier function, 
particularly those involved in antimicrobial defense mechanisms [50] and 
the establishment of TJs [51].  
 Experiments performed with human colonic explants showed that EcN 
vesicles promote upregulation of the antimicrobial peptide hBD-2. 
Epithelial hBD-2 plays an important role in intestinal barrier function. Its 
expression is known to be induced by some probiotics, including EcN, as a 
mechanism involved in their beneficial action [52]. The induction of hBD-2 
elicited by EcN OMVs might be attributed to flagella-associated proteins 
present in these vesicles [50]. In contrast, EcN OMVs do not significantly 
modify expression of β-defensin-1 (hBD-1), an antimicrobial peptide that 
acts as a component of host innate defenses at the intestinal surface. The 
lack of vesicle-mediated effects on hBD-1 is consistent with the                 
non-regulated, high constitutive expression of this antimicrobial peptide in 
colon epithelial cells.  
 Regarding the modulation of mucus production, the probiotic EcN has 
been shown to upregulate the expression of several mucins in intestinal 
epithelial cell lines [53]. In the gut mucin-2 (MUC-2), which is secreted by 
globet cells, is of special relevance since it is the main component of the 
intestinal mucus layer. However, up-regulation of MUC-2 by EcN seems 
not to be mediated by released OMVs [50]. 
 Another mechanism by which microbiota, and especially probiotic 
strains, help to strengthen the integrity of the intestinal barrier is through 
the regulation of TJ proteins. TJs are multiprotein complexes that regulate 
the paracellular trafficking of macromolecules. They seal the adjacent 
epithelial cells in a selective permeable form and determine the apical and 
basolateral parts of the membrane and thus, cell polarity. TJs are formed 
by four types of transmembrane proteins: occludin, claudins, junctional 
adhesion molecules, and tricellulin. TJs also contain proteins ZO-1, ZO-2 
and ZO-3, which bind to claudins and act as scaffolds anchoring the TJ 
transmembrane proteins to the actin cytoskeleton. Association of the            
ZO-proteins to TJ multiprotein complexes is regulated by phosphorylation 
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mechanisms. Specific kinases control the subcellular distribution of the TJ 
proteins and by end the strength of the epithelial barrier. Claudins 
constitute a large family of TJ proteins that regulate cell permeability and 
cohesion. In humans, this family includes 27 members. Some claudins 
have a sealing function, while others act as selective channels for small 
charged molecules. The pore- forming protein claudin-2 belongs to this 
last group and greatly contributes to the transepithelial water secretion.  In 
fact, stimuli that raise claudin-2 levels result in increased barrier 
permeability. 
 Several in vitro and in vivo studies performed with live EcN bacteria 
showed that this probiotic positively modulates the intestinal epithelial 
barrier through the positive regulation and redistribution of TJ proteins           
ZO-1, ZO-2 and claudin-14 [20,21,22]. Upregulation of claudin-14 was 
attributed to the secreted protein TcpC [22]. These studies, however, did not 
reveal whether extracellular vesicles could mediate these effects. In addition, 
the TcpC secretion mechanism was unknown. With this information 
different experimental approaches were set up to assess the ability of EcN 
OMVs to strengthen the epithelial barrier in different epithelial cell lines 
[50]. To distinguish between TcpC and vesicle effects, a TcpC deficient 
mutant was derived from EcN, and OMVs were isolated from both the             
wild-type and the mutant EcN strains. The effect of OMVs on the epithelial 
barrier was confirmed by measuring the increase in transepithelial electrical 
resistance (TER) of T-84 cell monolayers at 24 h post-incubation. The 
vesicle-reinforcement effect was independent of TcpC expression. The 
positive TcpC activity on the TER was associated with the soluble secreted 
fraction. These results prove that TcpC is not secreted by OMVs. 
 The regulatory role of EcN OMVs on the expression of TJ proteins 
was analyzed measuring the mRNA (RT-qPCR) and protein levels 
(Western blot and confocal fluorescence microscopy) of ZO-1, ZO-2 and 
claudin-14 (known to be regulated by the probiotic EcN),  and also the 
leaky protein claudin-2. EcN OMVs promote up-regulation of ZO-1 and 
claudin-14, and down-regulation of claudin-2. These effects are                    
TcpC-independent (Fig. 2). Interestingly, soluble secreted TcpC also 
positively regulates the expression of ZO-1 and claudin-14, but this protein 
has no effect on the transcriptional regulation of claudin-2. Concerning 
ZO-2, results showed that vesicles released by this probiotic do not 
regulate its expression. Thus, the EcN-mediated upregulation of ZO-2 does 
not rely on secreted factors but probably depends on bacteria-associated 
components. 
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Figure 2. Modulation of the intestinal epithelial barrier by EcN OMVs in an intact 
epithelial barrier model: EcN OMVs reinforce the epithelial barrier through the 
increase of TER and positive regulation of the ZO-1 and claudin-14 proteins, as well 
as the negative regulation of claudin-2. In addition, EcN OMVs increase the 
expression of the antimicrobial peptide β-defensin-2.  
 
 Thus, contribution of EcN OMVs on the reinforcement of the intestinal 
epithelial barrier integrity, through several mechanisms, has been proved 
[51]. As stated, EcN OMVs directly modulate transcriptional regulation of 
TJ proteins, but also elicit additional responses that indirectly contribute to 
strengthen the epithelial barrier. In this sense, we have reported that OMVs 
released by this probiotic induce IL-22 expression in colonic explants [50]. 
This cytokine, mainly expressed by immune cells, targets epithelial cells 
and reinforces the intestinal barrier, thus limiting the access of microbial 
compounds and allergens to the systemic circulation.  
 
5.4. Immunomodulatory role of EcN OMVs 
 
 As commented above, EcN is a good colonizer of the human gut and 
positively affects gastrointestinal homeostasis and microbiota balance.              
In addition to its beneficial effects on intestinal epithelial barrier, this 
probiotic modulates the host immune response towards an anti-inflammatory 
balance. The EcN-mediated effects have been mainly evidenced from a great 
number of in vitro and in vivo experiments performed with live probiotic 
suspensions [17,18,20,21,54]. Nonetheless, the bacterial factors that mediate 
these effects are not always known. 
 To define whether the immune modulation effects promoted by EcN are 
mediated through released OMVs, several in vitro and ex vivo cell models 
were set up to analyze the cytokine/chemokine response elicited by EcN 
OMVs in gut epithelial and immune cells [50].  
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(i)  Direct stimulation of peripheral blood mononuclear cells (PBMCs) was 
used as an in vitro model of intestinal inflammation and barrier 
disruption. Stimulation of these immune cells with EcN OMVs 
activates the expression and secretion of IL-10, MIP1α, TNF-α, IL-6 
and IL-8. In this model of inflamed barrier, bacterial lysates also 
trigger activation of these cytokines, even to a higher extent. 
(ii) Apical stimulation of Caco-2/PBMCs co-cultures in Transwell 
permeable supports. This in vitro model that mimics intact intestinal 
barrier allows evaluating the crosstalk between OMVs, intestinal 
epithelial cells and the underlying immune cells [55,56]. In this model, 
OMVs are not in direct contact with the immune cells. Therefore, upon 
apical stimulation OMVs are internalized by epithelial cells, and 
signaling between epithelial and immune cells is produced through the 
release of soluble mediators. Apical stimulation with EcN OMVs 
results in the activation of immunomodulatory responses in the 
underlying immunocompetent cells, leading to increased secretion of 
IL-10, MIP1α, TNF-α, IL-6 and IL-8 in the basolateral compartment. 
In this model of intact intestinal barrier, bacterial lysates do not 
produce any activation effect. Parallel experiments performed in  
Caco-2 monolayers without underlying PBMCs showed that polarized 
Caco-2 cells are almost unresponsive to bacterial factors in the absence 
of crosstalk with immune cells. Overall results from this model 
indicate that released EcN OMVs can mediate the probiotic 
immunomodulatory effects in the intact intestinal mucosa. This 
mechanism may also apply to microbiota-derived vesicles. 
(iii) Stimulation of human colonic explants, an ex vivo model closer to the              
in vivo gut conditions. Results in this model confirmed the great 
potential of EcN OMVs to modulate the immune response in intact 
intestinal mucosa, being the expression profile for the cytokines 
analyzed similar to that from the in vitro co-culture model. The genes 
encoding IL-10, MIP1α, TNF-α, IL-6 and IL-8 were upregulated in 
colonic explants incubated with EcN OMVs. In addition, vesicles from 
this probiotic diminished the expression of the pro-inflammatory 
cytokine IL-12.  
 
 The study on the immunomodulatory effects of EcN OMVs [50] proved 
the ability of probiotic vesicles to mediate signaling events to the immune 
system through the intestinal epithelial barrier. Thus, the beneficial effects of 
the probiotic EcN on gut homeostasis, especially modulation of the immune 
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response and barrier function, can be mediated by released OMVs. Our 
results with probiotic vesicles can be extrapolated to the microbiota-host 
crosstalk. Release of extracellular vesicles allows microbiota to 
communicate with intestinal mucosa cells, promoting the delivery of 
mediators that trigger host immune and defense responses.  
 
6. OMVs in the treatment of intestinal inflammatory 
diseases 
 
 Inflammatory bowel diseases (IBD) are chronic gut inflammatory 
disorders that have an increasing incidence worldwide, particularly 
ulcerative colitis (UC) and Crohn’s disease. They are multifactorial 
diseases that involve a dysregulated immune response against commensal 
gut microbes in genetically susceptible individuals with altered intestinal 
epithelial integrity [57]. Conventional IBD therapies including salicylates, 
corticoids, immunosuppressants and biological agents do not always yield 
good results [58]. As a common trait, IBD patients show an altered 
intestinal microbiota balance, a condition known as dysbiosis. For this 
reason several studies have evaluated the therapeutic effect of commensal 
and probiotic strains in clinical trials [59,60] or in animal models of colitis 
[35,37,61,62,63,64]. 
 Concerning EcN, various clinical trials have evidenced its therapeutic 
benefits in inducing and maintaining remission of UC, showing similar 
anti-inflammatory effects as the standard treatment with aminosalicylate 
mesalazine [65,66]. Several mechanisms contribute to the therapeutic 
action of EcN against IBD, including the modulation of the host immune 
response toward an anti-inflammatory balance, the ability to reinforce the 
intestinal epithelial barrier [20,21,22], production of antimicrobial factors 
such as microcins and the induction of epithelial  hBD-2 [18].  
 It has been reported that EcN OMVs could mediate the                             
anti-inflammatory and barrier protection effects reported for this probiotic 
in experimental colitis [67]. In this study, oral administration of                    
EcN OMVs was evaluated in the dextran sodium sulphate (DSS)-induced 
colitis mouse model. The experimental design included pre-treatment with 
EcN OMVs for ten days before DSS intake and a final five-day recovery 
period. The OMVs-treated group received EcN vesicles during all the 
experimental period (20 days). Administration of purified EcN OMVs 
significantly reduced DSS-induced weight loss and ameliorated clinical 
symptoms and histological damage. In addition, OMVs treatment 
counteracted the altered expression of cytokines and markers of intestinal 
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barrier function, thus proving the ability of EcN OMVs to ameliorate 
mucosal injury and gut inflammation.  
 Concerning microscopic analysis of colonic samples, the OMVs-treated 
mice showed preserved goblet cells replenished with their mucin content, 
and reduced mucosal infiltration areas, ulceration and oedema. Consistently, 
values for the colonic weight/length ratio were significantly smaller in this 
treated group than in the colitic control group. All these observations are 
consistent with an improvement in the mucosal barrier integrity in mice that 
received EcN OMVs. 
 The OMV-mediated anti-inflammatory effects were clearly evidenced 
by the improvement in the exacerbated immune response associated to 
colonic damage in DSS-treated mice. This treatment activates several cells 
of the innate immune response including epithelial cells, macrophages and 
dendritic cells, which leads to upregulated expression of pro-inflammatory 
cytokines such as IL-1β, TNF-α, and IL-6, thus triggering an imbalance in     
T-regulatory cells and Th1/Th17 cell responses. This regulatory network 
facilitates sustained inflammation through activation of other cytokines such 
as IFN-γ, IL-12 and IL-17 and also reduction of the anti-inflammatory 
cytokine IL-10 [68]. This altered cytokine expression profile was 
counteracted by EcN OMVs treatment by increasing IL-10 expression and 
diminishing expression of the anti-inflammatory cytokines [67].  
 One of the first events in intestinal inflammation is the impairment of 
the epithelial barrier function. This alteration enables the access of luminal 
antigens that trigger the exacerbated immune response. Therefore, promotion 
of mucosal healing is fundamental to prevent intestinal inflammation. One 
mechanism used by EcN OMVs to protect the intestinal barrier in                  
DSS-colitic mice is downregulation of MMP-9, a metalloprotease that 
disrupt gut epithelial TJs, thus leading to increased intestinal permeability 
[69]. In addition, this treatment preserves expression of the MMP-2, which 
displays an opposite role to MMP-9 [70].  
 Another factor that contributes to mucosal barrier function is the protein 
trefoil factor 3 (TFF-3). In conditions of intestinal inflammation, such as 
DSS-induced colitis, expression of TFF-3 is downregulated [71]. 
Interestingly, EcN OMVs were able to restore the mRNA levels of TFF-3 to 
values similar to those of healthy mice. Thus, upregulation of this peptide by 
EcN OMVs contributes to epithelial protection and repair, preserving the cell 
structure of the colonic mucosa in DSS-treated mice [67]. It is known that 
TFF-3 reinforces TJs by promoting the redistribution of ZO-1 from the 
cytosol to the intercellular junctions of intestinal epithelial cells, where 
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strongly interacts with occludin, without altering ZO-1 expression [72]. 
Although EcN OMVs upregulate ZO-1 expression in several intestinal 
epithelial cell lines [51] they do not compensate the reduced ZO-1 
expression in the DSS-experimental colitis model. This may reflect that EcN 
OMVs activate different regulatory mechanisms in the presence of highly 
expressed inflammatory mediators, including those that modulate ZO-1 
location at the TJ structures, such as TFF-3. In addition to the beneficial 
effects on epithelial barrier repair, upregulation of TFF-3 may also 
contribute to ameliorate the inflammatory response in DSS-treated mice, 
since overexpression of this peptide abolishes the IL-1β mediated 
upregulation of certain pro-inflammatory cytokines [73].  
 Other markers of tissue damage and inflammation upregulated in               
DSS-induced colitis are cyclooxygenase-2 (COX-2) and inducible oxide 
nitric synthase (iNOS). These enzymes confer protection against tissue 
injury, inflammation and infection and are highly expressed at damaged 
sites. Although iNOS upregulation is part of the intestinal antibacterial 
response that results on nitric oxide (NO) production, excess NO has been 
associated with intestinal inflammation in IBD patients [74], being the 
infiltrating macrophages in intestinal mucosa the main source of upregulated 
iNOS [75,76]. In these conditions, high levels of NO may cause tissue injury 
and the mucosal lesions observed in both human IBD and mouse 
experimental colitis. In DSS-treated mice, administration of EcN OMVs 
downregulates the altered expression of both enzymes, thus contributing to 
mucosal healing [67].  
 Oral administration of OMVs isolated from the probiotic EcN 
significantly reduces colonic damage in colitic mice [67]. These vesicles 
mediate anti-inflammatory and barrier protection effects, similarly to what 
has been reported for this probiotic in experimental colitis. The components 
of EcN OMVs responsible for these effects remain unknown. The polyketide 
colibactin could be one of these mediators. It is known that colibactin is 
required for the in vivo anti-inflammatory effects of EcN [49]. Moreover, in 
the DSS-induced colitis mouse model, administration of an EcN mutant 
deficient in colibactin synthesis results in exacerbated colitis. Although the 
colibactin secretion mechanism has not been described so far, the                    
anti-inflammatory effects of EcN OMVs in experimental colitis suggest that 
colibactin could be delivered to the intestinal mucosa, at least in part, 
through released vesicles. However, the contribution of other specific 
probiotic OMV-associated factors to the modulation of mucosal healing 
markers cannot be ruled out.  
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Figure 3. Antiinflammatory and barrier protection effects of EcN OMVs in DSS-
induced experimental colitis in mice. 
 
7. Concluding remarks 
 
 The influence of microbiota in human health is well known. Nowadays, 
microbiota imbalances (dysbiosis) have been associated with great variety of 
inflammatory and metabolic diseases. A therapeutic strategy to modulate 
microbiota composition is the administration of probiotics. This therapy is 
essentially an attempt to harness the beneficial effects of commensal 
microbiota. However, translation of probiotics or microbiota-based drugs to 
human healthcare requires knowledge of the molecular mechanisms 
involved in probiotic-host interactions. Moreover, although probiotics are 
Generally Regarded As Safe, some concerns about the potential risk 
associated with their use should be considered, especially in 
immunocompromised individuals and neonates.  
 Extracellular vesicles released by microbiota have a key role in   
bacteria-host cross-talk at the intestinal mucosa, as they act as a secretion 
and delivery pathway for selected bacterial proteins and active mediators 
directly to the host cells. Studies performed with the probiotic EcN prove the 
ability of the released vesicles to mediate signalling events to the immune 
system through the intestinal epithelial barrier, thus triggering appropriate 
host immune and defence responses. In addition, EcN OMVs mediates 
intestinal anti-inflammatory and barrier protective effects in the DSS 
experimental model of colitis.  
 Interestingly, isolated OMVs are free from bacteria and can elicit the 
same effect on gastrointestinal health as the probiotic itself. Thereby,              
EcN OMVs (either alone or in combination with secreted soluble factors) 
could represent a new therapeutic treatment with a high bio-safety level to 
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prevent and ameliorate inflammatory conditions associated with intestinal 
disorders. This potential formulation fits into the term postbiotic, a group of 
new potential treatments based on probiotic or microbiota products that is 
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Abstract. Alzheimer’s disease (AD) is the main neurodegenerative 
disorder worldwide. Its pathogenesis involves a network where 
various mechanisms are interconnected. This complex pathological 
network makes it extremely challenging to find an efficacious 
treatment. Herein, we give an overview on the design of the so-called 
multi-target-directed ligands, i.e. compounds that concurrently hit 
several key pathogenic factors within the network, as a realistic option 
to tackle AD, with a particular emphasis on some structural classes of 
multitarget hybrids recently developed in our group.              
 
Introduction 
       
      Alzheimer’s disease (AD) is characterized by an inexorable progressive 
deterioration in cognitive ability and capacity for independent living [1]. AD 
is the most prevalent neurodegenerative disorder and one of the most 
important health-care problems in developed countries. Over 47 million 
people live with dementia worldwide, and this number is estimated to increase 
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to more than 131 million by 2050, as populations age. Dementia also has a 
huge economic impact, with the total estimated worldwide cost being                
US $818 billion [2]. To aggravate this situation, current treatments against 
AD afford only temporary relief of the cognitive and functional symptoms, 
but do not prevent, halt, or delay disease progression. 
 During the past 40 years, intensive research efforts have aimed to 
decipher the mechanisms of AD progression. However, the etiology of AD is 
not yet completely understood, and the unique neuropathological clearly 
defined hallmarks are the senile plaques and neurofibrillary tangles (NFTs), 
which are mainly composed of aggregated β-amyloid peptide (Aβ) and 
hyperphosphorylated tau protein, respectively, together with a degeneration 
of the neurons and synapses [3,4]. The lack of success in discovering novel 
pharmaceuticals to tackle AD is very likely caused by the multifactorial 
nature of the disease, which involves various complex mechanisms where 
several key proteins and pathological pathways are interconnected in a 
robust network. Thus, we must conceive AD as a pathological network 
instead of a continuous process [5]. 
 Considering the mechanistic complexity involved in the pathological 
network of AD, it is easy to understand why the classic medicinal chemistry 
paradigm of developing drugs based on the reductionist approach of “one 
molecule-one target” has met with very limited success, which highlights the 
need for a more comprehensive pharmacological strategy to obtain effective 
outcomes. 
 In this context, some pharmacological approaches are available for the 
treatment of multifactorial diseases, such as AD. The most commonly used 
in general pharmacotherapy, referred to as multiple-medication therapy 
(MMT), consists of combining several drugs with different action 
mechanisms. However, this approach might imply patient compliance and 
pharmacokinetics issues [6,7]. An alternative approach relies on the use of a 
multiple-compound medication (MCM), which implies the incorporation of 
different drugs into the same formulation in order to simplify dosing 
regimens and improve patient compliance [6,7]. 
 Finally, a third strategy is based on the assumption that a single molecule 
may be able to hit multiple targets. This approach, the so-called multi-target-
directed ligand therapy (MTDL, Fig. 1), shows advantages over the 
aforementioned strategies, such as easier pharmacokinetics, improved efficacy 
due to synergistic effects, improved safety by preventing the risk of drug-drug 
interactions, and easier development, among others [6,8,9]. MTDLs can be 
rationally designed through the molecular assembly of distinct pharmacophore 
moieties of known bioactive molecules, where each drug entity has conserved 
the potential to interact with its specific site on the target [9]. 
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Figure 1. Different approaches to polypharmacological therapies against 
multifactorial diseases. Left: one-molecule-one-target strategy. Centre: multiple-
medication therapy (MMT); in case of multiple-compound medication (MCM), both 
drugs are applied in the same pill. Right: multi-target-directed ligand (MTDL) 
approach. 
 
 In this chapter, we briefly review the design of hybrid molecules with 
the aim of combating AD, either by increasing the potency against a specific 
target, or by using a MDTL strategy in order to concurrently affect several 
targets within the AD network. 
 
1. Increasing the potency against a key target, 
acetylcholinesterase 
 
 A common feature in AD patients is a cholinergic dysfunction, which 
is responsible for the clinical symptoms of the disease, which led to the 
postulation of the “cholinergic hypothesis of AD”. This hypothesis 
proposed that degeneration of cholinergic neurons and the associated loss 
of cholinergic neurotransmission contributed significantly to the 
deterioration in cognitive function, perception, comprehension, reasoning, 
and short-term memory, observed in patients with AD [10,11]. This 
abnormal acetylcholine (ACh) neurotransmission is caused by 
dysregulation at different levels of synapses, such as a decreased 
availability of ACh because of high-affinity choline uptake, reduced ACh 
release or reduced ACh synthesis [11,12]. 
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Figure 2. X-ray structure of hAChE (PDB ID: 3LII) with details of the CAS and the 
PAS. 
 
 At present, the most common therapeutic strategy aims at re-establishing 
the functional cholinergic neurotransmission by decreasing ACh metabolism 
through acetylcholinesterase inhibitors (AChEIs), which fit within the 
category of indirect cholinomimetic drugs [13]. Human AChE (hAChE) is 
the enzyme responsible for the hydrolysis of ACh, which takes place inside 
the catalytic anionic site (CAS) by means of the catalytic triad 
Ser203‐His447‐Glu334 (Fig. 2). A secondary binding site is the peripheral 
anionic site (PAS), which is located at the mouth of the narrow catalytic 
gorge and is responsible for the early binding and guiding of the substrate 
ACh towards the CAS [14,15]. 
 The “cholinergic hypothesis” has led to four out of the five marketed 
anti-Alzheimer drugs, which act as AChEIs and are only symptomatic and 
effective for a limited time. The first approved drug of this group was tacrine 
(1, Fig. 3) [16,17], although it was withdrawn from the market due to 
hepatotoxicity issues [18]. 
 
1.1. Huprines as a new class of highly potent AChEIs 
 
 An example of how the inhibitory activity against AChE can be greatly 
increased by achieving a larger number of interactions within the CAS of the 
enzyme was reported by the group of Camps and Muñoz-Torrero with the 
development of huprines, a new class of compounds that turned out to be 
among the most potent reversible AChEIs described so far [19-21]. Huprines 
were designed by a conjunctive approach, using as templates two well-known 
CAS inhibitors, namely (–)-huperzine A (2, Fig. 3), an alkaloid isolated from 
Huperzia serrata with potent AChE inhibitory activity that is commercialized  
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Figure 3. Design of huprines. 
 
as a nutraceutical in the USA [21], and tacrine (1). More than thirty different 
huprines were designed, synthesized and pharmacologically tested. The most 
active huprines prepared to date are the so-called (–)-huprine Y, (–)-3, and              
(–)-huprine X, (–)-4, which are, in racemic form, up to 640- and 810-fold more 
potent hAChE inhibitors than the parent compounds tacrine and (–)-huperzine 
A, respectively [21]. X-Ray diffraction studies confirmed the extended binding 
of huprines within the CAS of AChE as compared with the binding mode of 
their parent compounds, which accounts in a great part for the higher AChE 
inhibitory potency of huprines, thereby confirming the success of the 
hybridization strategy [22]. 
 
1.2 Benzonaphthyridine−tacrine hybrids as novel AChEIs 
 
 As a further step to increase AChE inhibitory activity by enlarging the 
number of interactions with the enzyme, the so-called dual site binding 
consists of the simultaneous interaction of a compound with the two terminal 
binding sites within the catalytic gorge of AChE, i.e. with the CAS and the 
PAS. An attractive example of rational design of a dual binding site AChEI 
with a dramatic improvement of inhibitory potency is the development of the 
benzonaphthyridine−tacrine hybrid 9 [23]. This hybrid compound features a 
tacrine-based CAS interacting unit linked, by means of a tether of suitable 
length, to a previously developed PAS interacting unit. 
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 Firstly, we carried out the design and synthesis of a PAS binding unit, 
structurally related to propidium (5, Fig. 4), a well-known PAS binding 
AChE inhibitor, which led to a pyrano[3,2-c]quinoline scaffold (6) [24]. 
Even though previous molecular dynamics (MD) simulations predicted that 
this structure would bind the PAS of AChE by means of π−π stacking 
interactions with residues Trp286 and Tyr72, compound 6 was found to be 
poorly active as AChEI (IC50 > 10 µM) [25]. Subsequent optimization of 
this PAS binding unit mainly involved the replacement of the oxygen atom 
at position 1 by a nitrogen. This structural modification should be 
accompanied by an increase in the basicity of the quinoline nitrogen atom, 
which, hence, should be protonated at physiological pH, thereby enabling 
additional cation−π interactions of the novel benzo[h][1,6]naphthyridine 
system (7, Fig. 4) at the PAS of AChE. MD simulations predicted an 
additional hydrogen bonding between the protonated pyridine nitrogen 
atom and the hydroxyl group of the PAS residue Tyr72 [26]. Compound 7 
turned out to be a potent PAS AChEI (IC50 = 65 nM), being 500-fold more 
potent than propidium and more than 150-fold more potent than the hit 6. 
 Afterwards, we developed a hybrid (9) that featured the PAS binding 
pharmacophore of 7 and a unit of the well-known CAS binding ligand           
6-chlorotacrine (8, an optimized derivative of tacrine, Fig. 5), a highly potent 
AChEI. Both moieties were connected through a 3-methylene linker, which 
was suggested by previous computational studies to be the most suitable to 
enable a dual site binding within AChE, thereby allowing the resulting 
hybrid to retain all the characteristic interactions of the parent compounds 
within the enzyme. Indeed, the 6-chlorotacrine fragment of the hybrid was 
predicted to be tightly bound at the CAS, with this moiety establishing 




Figure 4. Left: optimization process of PAS AChEIs. Right: representation of the 
binding mode of compound 7 at the PAS of AChE [26]. 
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Figure 5. Left: design of hybrid 9. Right: representation of the multi-site binding 
mode of hybrid 9 within AChE [23]. 
 
the protonated quinoline nitrogen with the carbonyl oxygen atom of His447. 
In turn, the benzo[h][1,6]naphthyridine moiety of the hybrid, whose 
quinoline nitrogen atom should be mostly protonated at physiological pH, 
was predicted to be firmly stacked against Trp286 at the PAS, establishing 
cation−π interactions. Remarkably, we found that an additional hydrogen 
bond could be formed between the amide group in the linker and Asp74. All 
this set of interactions along the catalytic gorge of AChE account for the 
extremely potent inhibitory activity of hybrid 9, beyond our expectations, in 
the low picomolar range (IC50 = 6 pM), with this compound being 1000-fold 
more potent than the reference compound 6-chlorotacrine (IC50 = 5.9 nM) 
[23]. 
 
2. Huprine-based MTDLs against AD 
 
 Senile plaques and NFTs, mainly composed of aggregated Aβ and 
hyperphosphorylated tau protein, respectively, constitute two 
histopathological hallmarks clearly defined in AD patients. Consequently, 
both events have brought about the pertinent hypotheses about the origin of 
AD pathology. Firstly, the “amyloid hypothesis” postulates that AD is 
caused by an imbalance between Aβ production and clearance, resulting in 
increased amounts of Aβ, whose accumulation and aggregation into 
oligomers, and eventually fibrils and plaques, leads to neuronal damage and 
cell death [27]. The central event in the amyloid hypothesis is an alteration 
in the metabolism of the amyloid precursor protein (APP), which is directed 
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to an amyloidogenic pathway in AD patients, by which the sequential 
cleavage of APP through β-secretase (BACE1) and γ-secretase, affords a     
39–43 amino acid polypeptide, Aβ, which is highly insoluble and shows 
strong tendency to aggregate [28]. In this regard, one of the most pursued 
targets in the search for new anti-Alzheimer drugs has been the modulation 
of Aβ production through BACE1 inhibitors [29]. BACE1 is an aspartic 
protease, whose active site contains two aspartate residues, Asp32 and 
Asp228, which are responsible for the initial cleavage of APP. The binding 
cleft is characterized for being partially covered by a highly flexible 
antiparallel hairpin-loop, referred to as the “flap”, which guides the entrance 
of the substrate into the catalytic site (Fig. 6) [30]. 
 On the other hand, the “tau hypothesis” postulates that AD patients 
suffer from an increased kinase activity, which triggers tau 
hyperphosphorylation, and detachment of the resulting distorted protein from 
the microtubules, so that the axon disintegrates and the skeleton of the 
neuron is no longer maintained. Without the cytoskeleton, neurons 
degenerate, and connections between neurons are lost, what eventually leads 
to apoptosis due to the loss of function [31,32]. Moreover, defective tau 
protein has a strong tendency to aggregate, forming paired helical filaments 
(PHF) inside the neuron, whose abnormal accumulation results in NFTs 
formation. Tau aggregation occurs through a nucleation-dependent 
elongation mechanism [33]. In fact, tau may adopt stable seed structures, 
displaying prion-like characteristics [34,35]. Therefore, prevention of tau 




Figure 6. Structure of BACE1 (PDB ID: 1SGZ) with the details of the catalytic 
anionic dyad and the “flap”. 
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2.1. Rhein−huprine hybrids as a new class of anti-Alzheimer MTDLs 
 
 The multifactorial nature of AD led to the establishment of the MTDL 
strategy as a promising, realistic therapeutic approach. In this context, 
rhein−huprine hybrids were designed as a novel structural family of MTDLs. 
This class of compounds had its origin in the finding that compounds sharing 
a core structure of hydroxyanthraquinone displayed tau anti-aggregating 
properties in vitro with IC50 values in the low micromolar range [36,37]. The 
structurally related compound rhein (10, Fig. 7, left) is a natural product 
found in the traditional Chinese herbal medicine rhubarb (Rheum rhabarbarum),  
which is well tolerated in humans [38]. We assumed that the 
hydroxyanthraquinone derivative rhein could also display tau anti-
aggregating activity. Accordingly, the first generation of rhein–huprine 
hybrids was designed by connecting the hydroxyanthraquinone system of 
rhein and a moiety of the potent AChEI huprine Y (3) with a linker of 
suitable length. The lead compound of this family turned out to be the 
nonamethylene-linked hybrid (±)-11 [39,40]. 
 This family of hybrids was endowed with a very interesting in vitro and 
in vivo multi-target profile, especially the lead compound (±)-11 (Fig. 7, 
right). Not unexpectedly, this compound displayed cholinergic activity 
through a potent inhibition of human AChE and butyrylcholinesterase 
(hBChE), and Aβ42 and tau anti-aggregating activity. But more surprisingly,  
                          
 
Figure 7. Left: rhein, 10, the lead compound of the first generation of rhein–huprine 
hybrids, (±)-11, and the p-phenylene-linked analog (±)-12. Right: multi-target 
biological profile of the lead compound (±)-11. 
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the lead compound (±)-11 was also found to be a potent inhibitor of 
hBACE1, which led to a significant Aβ lowering effect in a transgenic 
mouse model of AD (APP/PS1 mice) [39,40]. 
 To shed light on the binding mode within hAChE, molecular modeling 
studies were carried out for the p-phenylene-linked rhein–huprine hybrid 
(±)-12, a less flexible analog of (±)-11, which was still a potent hAChEI, 
with an IC50 value of 18 nM. These studies suggested that the potent 
inhibitory activity of these hybrids against hAChE arises from a dual site 
binding within the enzyme [40]. Likewise, a dual site binding was also 
predicted with regard to hBACE1 inhibition, with the huprine moiety 
interacting with the catalytic dyad and the rhein fragment interacting with an 
unexplored secondary binding site [40]. 
 Of note, the huprine moiety, protonated at physiological pH, remains 
tightly bound to the catalytic site in both hAChE and hBACE1 by means of 
hydrogen bonding interaction with His447 and cation–π interactions with 
Trp86 and Tyr337 at the CAS of AChE, and a salt bridge with the catalytic 
dyad of BACE1. The basicity of the huprine moiety of these hybrids is 
therefore crucial for AChE and BACE1 inhibition, due to the need of being 
protonated at physiological pH to enable these strong interactions [40]. 
 
2.2. Second generation rhein−huprine hybrids 
 
 In general, compounds with high basicity suffer from low brain 
exposure as a result of poor permeation through biological membranes, 
particularly the blood-brain barrier (BBB), and high P-glycoprotein (P-gp)-
mediated efflux liability [41,42]. Hence, tuning of drugs pKa has been an 
approach widely adopted to increase drug concentrations in brain [41,43]. In 
this light, a second generation of rhein−huprine hybrids was envisaged in 
order to explore how modulation of their basicity would affect their multiple 
biological activities, while trying to improve their pharmacokinetic 
properties. In the case of BACE1 inhibitors, the optimal balance between the 
relevant properties of enzymatic potency and pharmacokinetics has been 
reported for compounds with pKa values between 7 and 7.5 [44]. 
 For the design of the novel hybrids, the lead compound 11 was used as a 
template. Structural modification of its huprine moiety, i.e. the replacement 
of the chlorobenzene ring by other aromatic rings, should modify the 
basicity of the pyridine nitrogen. The selection of the novel huprines was 
made on the basis of their calculated pKa values by means of high-level 
quantum mechanical (QM) computations. In this way, we selected the              
1,4-difluorohuprine 13a (Fig. 8, left) and the thienohuprine 13b, with 
reduced basicity compared with huprine Y (pKa = 8.2, for the N-methylated  
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Figure 8. Left: selected modified huprines, (±)-13a-d, and their calculated pKa values 
determined for the N-methylated derivatives by QM computations. Right: novel 
rhein–huprine hybrids, (±)-14a-d. 
 
derivative of huprine Y), and the naphthyridine-based huprine 13c [45] and 
the methoxyhuprine 13d, which were predicted to be slightly more basic 
than huprine Y [46]. BACE1 localizes and is fully active in acidic 
endosomal compartments (pH 4.5–6.5) [47,48,49], where all the novel 
rhein–huprine hybrids, 14a-d (Fig. 8, right), should be mostly in protonated 
form and therefore able to form a salt bridge with the aspartate residues of 
the catalytic dyad. On the other hand, AChE is located at physiological pH in 
synapses, where the most basic hybrids 14c and 14d should be mostly 
protonated, thereby retaining their AChE inhibitory activity, while the least 
basic hybrids 14a and 14b should predominate in the neutral form, with the 
consequent loss of hydrogen bond and cation−π interactions at the CAS of 
AChE. 
 It has been previously reported that replacement of the chlorobenzene 
ring of huprines by other aromatic systems is detrimental for the AChE 
inhibitory activity [20,21,45]. In agreement with these previous findings, all 
novel hybrids were clearly less potent than the lead compound 11, but they 
still exhibited IC50 values in the submicromolar to low micromolar range, in 
most cases. As anticipated, the most potent second-generation hybrids were 
those of increased basicity, especially the naphthyridine derivative 14c                   
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(IC50 = 180 nM), since they should retain their ability to bind at the CAS of 
AChE. The lower inhibitory potency of hybrid 14c compared to the lead 11 
was studied by means of QM computations and showed unfavorable 
secondary interactions due to the electrostatic repulsion between the lone 
pairs of the nitrogen atom at position 1 and of the His447 carbonyl oxygen 
[46]. Moreover, the decreased activity of 14c might be ascribed to the 
absence of the chlorine atom present at position 3 of huprine Y, which fills a 
hydrophobic pocket near the CAS. 
 On the other hand, hybrids 14a and 14b displayed some hBACE1 
inhibitory activity (22% inhibition at 1 µM, and 34% inhibition at 80 nM, 
respectively), whereas compounds 14c and 14d turned out to be essentially 
inactive. Again, this series of compounds was clearly less potent than the lead 
11, despite the fact that all novel second-generation rhein–huprine hybrids 
should be protonated at the acidic pH in endosomal compartments where 
BACE1 is located. According to QM calculations, unfavorable electrostatic 
interactions of the thiophene derivative 14b with the carboxylate oxygens of 
the catalytic dyad of BACE1 might account for its lower potency compared 
with the lead compound 11 [46]. 
 Furthermore, this second generation of rhein–huprine hybrids retained 
the Aβ42 anti-aggregating activity, while displayed slightly increased tau 
anti-aggregating properties, compared with the lead compound 11.                   
A common feature of AD is the oxidative damage in cellular structures, 
which occurs after an overproduction of reactive oxygen species and a 
deficiency of the antioxidant systems. Thus, we also assessed the 
antioxidant capacity of this novel series of compounds because of the 
presence of phenolic groups in their structure, and since it had been 
previously reported that rhein as well as huprine Y and a class of           
huprine-based hybrids were endowed with antioxidant properties 
[50,51,52]. Very interestingly, all the novel hybrids turned out to be potent 
antioxidant agents, being 10–22-fold and 12–13-fold more potent than 
trolox in the ABTS˙
+
 and DPPH assays, respectively, and slightly more 
potent than gallic acid [46]. Interestingly, using the PAMPA-BBB assay, 
all the hybrids were predicted to have good BBB permeability, a necessary 




 Novel approaches have to be explored to identify drugs that can 
efficiently treat AD. Focusing on the symptomatic treatment of AD by 
means of cholinomimetic agents, we have shown that molecular 
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hybridization is an effective strategy to derive extremely potent 
(subnanomolar or picomolar) AChEIs that display a wide array of 
interactions either at the CAS of the enzyme (e.g. huprines) or in a dual site 
manner, from the CAS to the PAS, all along the AChE catalytic gorge (e.g. 
benzonaphthyridine-chlorotacrine hybrids). More interestingly, molecular 
hybridization is an essential tool to design MTDLs, in a very promising 
approach to derive new drugs that are able to confront the complex 
pathological network of AD, and, hence, to modify the natural course of this 
devastating disease. Results from preclinical studies with animal models of 
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Abstract. Numerous strategies have been proposed to overcome the 
blood-brain barrier (BBB) and efficiently deliver therapeutic agents to 
the brain. One of these strategies consists of linking the 
pharmacologically active substance to a molecular vector that acts as a 
molecular Trojan Horse and is capable of crossing the BBB using a 
receptor-mediated transcellular transport system of the brain capillary 
endothelial cells (BCECs). The transferrin receptor (TfR) is related to 
a transcytosis process in these cells, and the 8D3 monoclonal antibody 
(mAb), directed against the mouse TfR, is able to induce a receptor 
response. Thus, the 8D3 antibody could be a potential molecular 
Trojan Horse to transport pharmacologically active substances across 
the BBB. On these bases, a series of experiments were performed 
where the 8D3 antibody was conjugated to different cargoes,                    
the resulting constructs were administered in vivo to mice, and the 
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distribution and intracellular mechanisms that these constructs undergo at the BBB were 
studied. Our results indicated a TfR-mediated and clathrin-dependent internalization 
process by which the 8D3-cargo constructs enters the BCEC. The resulting endocytic 
vesicles follow at least two different routes. On one hand, most vesicles enter intracellular 
processes of vesicular fusion and rearrangement in which the cargo is guided to late 
endosomes, multivesicular bodies or lysosomes. On the other hand, a small but not 
negligible percentage of the vesicles follow a different route in which they fuse with the 
abluminal membrane and open towards the basal lamina, indicating a potential route for 
the delivery of therapeutic substances. In this route, however, the 8D3−cargo remain fixed 
to the abluminal membrane, indicating that the 8D3 is maintained linked to the TfR, and 
the cargo does not go beyond the basal membrane. Altogether, different optimization 
approaches need to be developed for efficient drug delivery, but receptor-mediated 




       
      The blood-brain barrier (BBB) is a well-coordinated and highly selective 
barrier whose main function is to regulate brain homeostasis and the 
transport of endogenous and exogenous substances between the blood and 
the brain. It permits the selective brain uptake of nutrients and impedes the 
entrance of potentially harmful substances and pathogenic organisms into the 
brain [1-3]. Due to this restrictive nature of the BBB, the transport of 
therapeutics from the blood to the brain results extremely difficult, and has 
become a major pharmaceutical challenge in recent decades [1]. Only 
lipophilic molecules with a molecular mass under a 400-600 Da threshold 
are capable of crossing the BBB [1, 4]. Moreover, efflux transport systems 
such as P-glycoprotein, which are present in the brain capillary endothelial 
cells (BCECs), are able to export some of these small drugs back to the 
blood [5]. Hence, 98% of all small drugs and almost 100% of large molecule 
drugs are unable to cross the barrier [6]. 
 Different strategies have been proposed to transport neurotherapeutics 
from the blood into the brain, including the utilization of the receptor-
mediated transport (RMT) mechanisms present in the BCECs [1, 7]. The 
transferrin receptor (TfR), which is abundant in brain capillaries [7], has 
been extensively studied. Some monoclonal antibodies (mAbs) directed 
against this receptor have shown to be useful tools for studying                      
TfR-mediated transcytosis across the BBB in rodents, and have been 
proposed as possible vectors or molecular Trojan Horses to transport 
substances across the BBB [8-14]. Some studies have concluded that               
anti-TfR mAbs accumulate in BCECS and do not cross the BBB, while other 
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studies, most of which have used the capillary depletion method or indirect 
outcome measures such as protein expression or enzymatic activity, have 
concluded that mAbs and/or their cargo are successfully transported across 
the BBB [8, 12, 14-16]. Thus, whether or not mAbs directed against the TfR 




Figure 1. The proposed model for the transport of drugs across the BBB using RMT 
and anti-TfR mAbs includes: 1) the endocytosis of the drug-mAb/TfR on the luminal 
membrane and 2) the exocytosis of the mAb-drug on the basolateral membrane and 
receptor recycling. However, other possible destinations for the drug-mAb/TfR 
complex can be possible, as: 3) accumulation of the drug-mAb/receptor complex 
inside the BCEC, and 4) mAb and drug degradation. 
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 The rat mAb 8D3, directed against the mouse TfR, has been proposed as 
a potential carrier candidate to transport substances across the mouse BBB. 
This mAb was first produced by Britta Engelhardt’s research group in the 
Max Planck Institute (Bad Nauheim, Germany) [11], and some active 
substances that have been used as a cargo, seemed to achieve better results in 
crossing the BBB when attached to the 8D3 [14, 17-21]. However, the 
intracellular mechanisms the mAb or the mAb-cargo construct undergo 
inside BCECs still need to be elucidated. 
 The lack of more exhaustive analysis by means of microscopic 
techniques that allow the detection and direct localization of the mAb and / 
or cargo at a cellular and subcellular level, as well as the existing 
unknowledge regarding the cellular and intracellular processes that take part 
in the processing of these molecular Trojan Horses at the BBB level, have 
been the basis for the approach of this work. 
 In order to test the viability of the 8D3 as a potential carrier, a series of 
experiments were performed where the 8D3 antibody was conjugated to 
different cargoes, the resulting constructs were administered in vivo to mice, 
and the distribution and intracellular mechanisms that these constructs 
undergo at the BBB were studied. 
  
1. The 8D3 antibody is able to recognize TfR and trigger the 
internalization of the cargo which is conjugated to [adapted from 
22] 
 
 First of all, in order to test the reactivity of the 8D3 antibody for the TfR 
present in the luminal membrane of the BCECs, an inmmunohistochemical 
procedure was applied using 8D3 as the primary antibody on cryostat 
sections of mouse brain (male ICR-CD1). As expected, the staining 
permitted the visualization of brain capillaries (Figure 2A), where the BBB 
is present and the TfR is localized in the endothelial cells, but did not allow 
to visualize the vessels of the choroid plexus, in which the capillaries are 
fenestrated and the endothelial cells do not present TfR. 
 The second step was to test whether this antibody could be detected in 
brain capillaries after in vivo administration. For this purpose, a second 
group of animals underwent i.v. administration of 8D3 antibody in the 
caudal vein, and after 20 min of recirculation, brain samples were taken and 
localization of the 8D3 was determined via immunohistochemical 
techniques. The results showed that, in the same regions observed by direct 
immunohistochemistry, the brain capillaries contained the 8D3 antibody 
(Figure 2B1 and 2C1). They were stained with only the secondary antibody 
directed against 8D3, indicating that intravenously administered 8D3 
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antibody reaches and attaches to the BCECs. A simultaneous staining 
performed with laminin (a component of the basal membrane used to delimit 
the abluminal wall of the capillaries) showed that the laminin staining 
surrounded the 8D3 staining, suggesting that the antibody does not complete 
transcytosis, is unable to reach the cerebral parenchyma and remains inside 
the endothelial cell (Figure 2C3). It can also be observed that the 8D3 
antibody presented a granular pattern (Figure 2C1 inset), which contrasted 
with the fine and smooth staining of the laminin (Figure 2C2 inset). This 
granular pattern suggested some endocytic process by which the antibody 
could have been internalized inside the BCEC. 
 After observing that the intravenously administered 8D3 antibody can be 
localized in the wall of the brain capillaries, our next goal was to develop an 
immunocomplex (IC) composed of the 8D3 antibody (molecular                            
Trojan Horse) and Fab’ fragments (that simulated a cargo) attached to the 
8D3, and study the capacity of this antibody to transport the Fab’ fragment 
across the BBB. A third group of animals received an i.v. injection of the 
8D3-Fab’ ICs in the optimal proportions established previously                                             
(1:4 weight/weight 8D3/Fab’). After different times of recirculation                   




Figure 2. (A) Immunohistochemical labeling of mouse brain sections with the 
primary rat 8D3 MAb targeting murine TfR and the secondary AF488 anti-rat IgG 
(green color). (B and C) Brain sections from a representative mouse which received 
the 8D3 antibody intravenously. The sections were stained with an anti-laminin 
antibody as a primary, and both the AF555 (red color) and the AF488 anti-rat IgG 
(green color) as secondary antibodies to detect, respectively, the anti-laminin 
antibody and the administered 8D3. It can be observed that, after intravenous 
administration of 8D3, the antibody could be found in brain capillaries but not in 
parenchyma. The granular pattern of the 8D3 staining (C1 inset) contrasts with the 
uniform staining of the laminin (C2 inset). Scale bars: 10 µm.  [adapted from 22]. 
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brains were obtained in order to study the localization and colocalization of 
both components of the IC by immunohistochemistry. Using a fluorescence 
microscope, we observed that both components localized in the wall of the 
capillaries (Figure 3A1 and 3A2), with a clear granular pattern and high 
colocalization between the two stains (Figure 3A3), indicating that both 
components of the IC remain attached or at least where in the same 
endosomal compartment. The simultaneous staining with laminin (Figure 3B 
and C) demonstrated that both 8D3 and Fab’ cargo get externally delimited 
by this marker. In control animals that received an i.v. injection of an IC 




Figure 3. Localization of the components of the IC (8D3:Fab’ 1:4) in brain 
capillaries of the hippocampus. (A) Localization of the 8D3 antibody with a 
secondary AF488 (green color) and of Fab’ components with a secondary AF555 
(red color). High colocalization (yellow color) of 8D3 and Fab’ can be observed, and 
both components exhibit a granular pattern. (B and C) Simultaneous staining of 
laminin and 8D3 or Fab’ components. 8D3 and Fab’ seem to be localized inside the 
region delimited by the basal lamina. Scale bars: 10 µm. [adapted from 22]. 
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the IgG nor the Fab’ staining was observed in brain sections, hence 
indicating that the IC is not retained in the BCECs if it does not include an 
antibody directed against the TfR. 
 In order to study the maintenance and stability of the IC in the wall of 
the blood vessels through the different recirculation times tested (2.5 h vs              
24 h), we used the Fluorescence Resonance Energy Transfer (FRET) 
technique. As the ICs are formed by 8D3 rat IgG and goat anti-rat IgG Fab’ 
fragments, they can be simultaneously immunostained with AF488 donkey 
anti-rat IgG and AF555 donkey anti-goat IgG. Microscope images of AF488 
emission (green color) directly stimulated by its excitation frequency (blue 
color), were taken before and after bleaching AF555. When AF555 is 
bleached, it is incapable of capturing the emission of the AF488 that is 
emitted near to it (energy transfer), and thus, the detection of the donor 




Figure 4. Process performed for one blood capillary using the FRET technique. 
When AF555 is bleached, it is incapable of capturing the green emission of the 
AF488 that is emitted near to it (energy transfer), and thus the observed donor 
emission (D2) after bleaching the AF555 is bigger than before bleaching (D1).                  
A: acceptor emission, D: donor emission, 1: before bleaching, 2: after bleaching 
[adapted from 22].  
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 Thus, by quantifying the increase of the detected donor emission, an 
indication of the number of molecules implicated in the energy transfer, i.e. 
molecules of AF488 and AF555 that are near one to the other, can be 
obtained. Statistical analysis indicated that the time of recirculation had a 
significant effect on the increase of the detected donor emission, being the 
increase higher in animals that were sacrificed 2.5 h after IC administration 
than in animals sacrificed 24 h later. As AF488 and AF555 stain respectively 
the 8D3 and the Fab’ fragments, the increases also indicate the amount of 
8D3 and Fab’ fragments that persist attached on the original ICs. Thus, the 
colocalization of the fluorescent signals inside the endothelial cells 
decreased with time, indicating that ICs are processed and Fab’ fragments 
probably separated from 8D3. 
 On the other hand, in order to directly visualize the 8D3 antibody and 
avoid the immunohistochemical processing, a fourth group of animals 
received an i.v. injection of 8D3 previously marked with fluorescein 
isothiocyanate (8D3
FITC
). Likewise, another group of animals underwent i.v. 









 (data not shown) showed similar 
staining patterns in comparison with the anterior cases, being once again 
externally delimited by the laminin. However, a higher signal amplification 
was observed in the case of the 8D3-Fab’
FITC
 with respect to 8D3
FITC
, 




Figure 5. Localization of intravenously administered 8D3-Fab’FITC (green color) and 
immunohistochemical staining with a primary antibody against laminin and 
secondary AF555 anti-rabbit IgG (red color) in brain capillaries of the hippocampus. 
The fluorescence of the administered IC is confined to the region delimited by 
laminin. Scale bar: 10 µm [adapted from 22]. 
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 As concluding remarks, we observed that the 8D3 antibody, with or 
without a cargo attached, is able to bind the TfR present in the luminal 
membrane of the BCECs and gets retained in these cells, probably in 
intracellular vesicles. Inside these cells, some kind of IC processing is 
produced, and after 24 h of recirculation, there were less Fab’ fragments near 
the 8D3 molecules than after 2.5 h of recirculation. In any case, the 
components of the IC were never observed beyond the basal membrane or 
reaching the brain parenchyma. Thus, nor the 8D3 neither the IC seem to 
have completed transcytosis. These results cast doubt on the transcytotic 
capacity of the 8D3 antibody, and contradict previous studies that advocate 
an efficient transcytosis. However, the highest magnification level the 
optical microscopy allows us to work with, is perhaps not enough to draw a 
reliable conclusion, and we cannot rule out that an undetectable amount of 
antibody could have crossed the BBB.  
 
2. 8D3-cargo constructs at the BBB: Intracellular mechanisms 
and subcellular localization [adapted from 23] 
 
 In view of the results obtained, the next step to move along in the study 
of the 8D3 antibody was to monitor in a more precise way the antibody 
localization and clarify which intracellular processes take part at the BBB. 
 For this purpose, gold nanoparticles (AuNPs) were coated with the 8D3 
antibody, and using transmission electron microscope (TEM) techniques, the 
passage of these AuNPs across the BBB and their dynamics inside BCECs 
after in vivo administration were studied in mice. AuNPs not only can be 
directly observed by TEM, but also can be considered as the cargo to be 
transported by the 8D3. To form the 8D3-AuNP conjugates, the 8D3 
antibody was covalently attached to AuNPs measuring 20 nm in diameter. 
The 8D3:AuNP ratio for the conjugates was approximately of 30:1. The 
conjugate was intravenously administered to ICR-CD1 mice that were 
distributed into four different groups, each of them with a different time of 
recirculation (10 min, 30 min, 2.5 h and 24 h). Once the corresponding time 
had passed, animals were anesthetized and intracardially perfused with 
paraformaldehyde and glutaraldehyde, and brains were then removed and 
processed for TEM. 
 Image analysis permitted the study of the AuNP localization at a 
subcellular level and at the different times of recirculation. The localization 
patterns varied over time. At the shortest time of recirculation (10 min), the 
AuNPs were mostly attached to the lumen of the capillary, in clathrin-coated 
pits or internalized in endocytic vesicles of the endothelial cells that 
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contained one or few AuNPs inside. The 8D3-AuNP conjugates are 
individually internalized, as no clathrin-coated pits containing more than one 
AuNPs were observed. No AuNPs were observed in the brains of the control 
mice, which had been administered with intravenous non-specific IgG-AuNP 
conjugate, confirming that the internalization depended on the presence of 
the 8D3. At 30 min of recirculation, the percentage of AuNPs yet to be 
internalized had decreased, and some of the intracellular vesicles contained a 
higher number of AuNPs. At the highest times of recirculation (2.5 h and              
24 h), almost a 100% of the AuNPs observed had already been internalized 
in the BCECs, and many of the AuNP-containing vesicles had a higher 
number of particles inside them (up to 23 AuNPs in two cases). Some of the 
AuNPs were found in the basal lamina of the endothelium, bordering the 
abluminal membrane of the BCECs, which would suggest that 8D3-AuNP 
complex had completed transcytosis but remained attached to the TfR. Most 
of these AuNPs were observed at 2.5 h of recirculation, being 4.6% the 
percent respect to the total number of the AuNPs observed at this time 




Figure 6. Percentage of AuNPs on the luminal surface [i.e. particles attached to the 
luminal membrane (LMP) and particles in clathrin-coated pits (CPP)] and basal 
membrane (BMP) for each recirculation time. Mean values and standard errors are 
shown. L: Lumen; BM: basal membrane. At 2.5 h of recirculation, all particles have 
been internalized, and the maximum percentage of particles that reach the basal 
membrane is obtained [adapted from 23]. 
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 Thus, at the shortest times of recirculation (10 min and 30 min), the 
predominant localization patterns were the lumen of the capillary, the 
clathrin-coated pits and the endocytic vesicles containing small amounts of 
AuNPs. Apart from the AuNPs that reach the basal lamina, the number of 
AuNPs per vesicle increased over time, so that at the longer times of 
recirculation, the vesicles containing high amounts of AuNPs was the main 
localization pattern (Figure 7). 
 The quantitative analysis performed with the data obtained permitted to 
establish and characterize a time-dependent trafficking pattern of endocytic 
internalization and endosomal processing of the conjugate at the BBB 
(Figure 8). The 8D3-AuNP conjugates are individually internalized within 
BCECs through a clathrin-dependent endocytosis process. The resulting 
AuNP-containing vesicles then follow at least two different routes. On one 
hand, most vesicles undergo intracellular processes of vesicular fusion and 
rearrangement in which the AuNPs end up accumulating in late endosomes, 




Figure 7. 3D contour graph obtained by adjusting, with distance weighted                   
least-squares, the percentage of particles to the localization and the recirculation time. 
LMP: particles sited on luminal membrane; CPP: coated pit particles; Vi: vesicle 
containing i AuNPs. Particles sited on basal membrane are not plotted. L: Lumen; 
BM: basal membrane [adapted from 23]. 
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Figure 8. Deduced trafficking of the 8D3−AuNPs across the mouse BBB [adapted 
from 23]. 
 
On the other hand, a small percentage of vesicles (containing just one AuNP) 
follow a different route in which they fuse with the abluminal membrane and 
open to the basal lamina, which suggests an endosomal escape and 
transcytosis completion. However, the conjugates get retained in the basal 
lamina and do not reach the brain parenchyma. 
 Given the controversy regarding the possible use of anti-TfR antibodies 
to transport substances across the BBB, this study provided new information 
that may clarify some questions that are yet to be answered concerning the 
dynamics and intracellular processes the cargo undergo when coated with 
the 8D3 antibody. The results suggest that the 8D3 antibody may be a useful 
Trojan Horse to transport substances toward the BCECs. The 8D3 is able to 
drive the cargo to the brain capillaries and internalize it into the BCECs. 
This makes that a considerable amount of the intravenously administered 
cargo gets retained in the cerebral area instead of targeting another tissues or 
organs, and moreover, it makes the cargo to overcome the first barrier (the 
luminal membrane) reaching the inside of the endothelial cells. Although the 
cargo is mainly retained inside the BCEC, a small but not negligible 
percentage of particles escape from the conventional endosomal route, 
complete transcytosis and access the basal lamina, probably as a result of a 
different and uncommon endosomal sorting. This small percentage do not 
reach the brain parenchyma, perhaps due to the strong bond between the 8D3 
and the TfR. Nevertheless, it should not be considered impossible for the 
cargo to reach the brain parenchyma once it has reached the basal lamina if 
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the linkage between the Trojan Horse and the transported cargo had 
properties that permitted the cargo to dissociate from the carrier. 
 
3. Serial block-face scanning electron microscopy: A tool to       
three-dimensionally study the trafficking of mAb-cargo 
conjugates at the BBB [adapted from 25] 
 
 The results obtained by TEM provided relevant information at an 
ultrastructural level concerning the dynamics of the AuNPs when transported 
by the 8D3 antibody after in vivo administration. However, the                 
two-dimensional (2D) image analysis entailed a series of limitations that we 
decided to overcome by carrying out a three-dimensional (3D) structural 
study that could give more insight into the transport of molecules across the 
BBB, and more knowledge on the trafficking of the AuNPs. 
 Serial block-face (SBF) imaging is a recently developed imaging 
technique that uses scanning electron microscopy (SEM) to acquire serial 
images and reconstruct large tissue regions in 3D [24]. In SBF-SEM, surface 
areas of the embedded tissue blocks are serially cut and removed with the 
built-in diamond knife in the SEM chamber between the cycles of SEM 
imaging. Because the consecutive areas of tissue are imaged with surface 
milling, this method generates largely pre-aligned images, which speeds up 
3D reconstruction of the target structures. The objective of this work was 
first to determine whether the SBF-SEM resulted appropriate to reconstruct 
BBB segments and AuNP-containing endocytic vesicles, and if so, try to 
obtain additional information that would complement our previous 2D 
studies. This technique has been extensively used to explore the connectivity 
of the neural network, but only rarely to study the structure of the BBB, and 
no SBF-SEM data exist on the transport of molecules across this barrier. 
 To this end, we performed the same experimental design as for the 2D 
TEM study, but it was only reproduced at 2.5 h of recirculation (the time of 
recirculation where more diverse localization patterns were observed). After 
the mice brains were processed for SBF-SEM, the stained blocks were 
imaged using a Gatan 3View serial block-face imaging system installed on a 
FEI Quanta 250 FEG scanning electron microscope. The resulting datasets 
were assembled into volume files and aligned. 3D reconstruction of the 
desired structures was performed in image stacks using Imaris 8.0.2 and 
Imaris 7.2 software.  
 In a first attempt to perform a 3D reconstruction of the BBB and to 
observe the localization of the AuNPs, capillary segments (up to 10 µm long 
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along the z axis) from different brain samples were fully 3D rendered 
using low-magnification image stacks (10,000-25,000×). These image 
stacks were obtained using an incident electron beam with an energy of 
2.3-2.4 kV and spot size 3, and a chamber pressure of 50 Pa was applied to 
scan across the samples at a pixel dwell time of 60 µs. This level of 
magnification allowed us to identify the cellular components that form the 
neurovascular unit, such as BCECs, the basal lamina, pericytes, astrocytes, 
and three-dimensionally reconstruct them by manually tracing the area in 
each plane and surface rendering next (Figure 9). However, the AuNPs 
could not be clearly visualized, neither inside nor outside endocytic 
vesicles. This was due, on one hand, to the low resolution in the x-y plane, 
and on the other hand, due to the backscattered electron signal. Moreover, 
it must be pointed that the presence of bare resin in the lumen of the 
capillary caused electrical charging of the sample, and consequently, tissue 
deterioration or breakage. 
 Due to these technical problems, a second attempt with higher 
magnification imaging (>30,000×) of the capillary segments was 
considered, avoiding the inclusion of the whole lumen in the region of 
interest (ROI). We used an incident electron beam with an energy of                
3.5 kV and spot size 3, and a chamber pressure of 50 Pa was applied to 
scan across the samples at a pixel dwell time of 60 µs. At this level of 
magnification, BCEC segments and the basal lamina of the endothelium 
could be observed, as well as both the vesicles inside the BCECs and the 
AuNPs contained in them. The sequential images in the stack allowed us to 
3D render structures such as the basal lamina or the vesicles located inside 
the BCECs by manually tracing the area in consecutive planes (Figure 10). 
Although the AuNPs were visible, due to their small size, it was 
impossible to 3D render them using this method; they are located in one or 
another section, but never in more than one, so it was impossible to 
reconstruct these particles in 3D by manually tracing the area across 
consecutive planes. Thus, a copy of the stack was preprocessed using the 
Fiji software to later replace the AuNPs in each section by 3D spheres of 
similar size (20 nm diameter) in Imaris. Since the AuNPs are the darkest 
structures in these images, they could be segmented with the Fiji software 
using a low threshold value. After segmentation, the resulting binary 
particles were split using a watershed to allow individual reconstruction. 
The final binary stack of images was loaded into Imaris as an additional 
channel of the original stack and the AuNPs were rendered as spheres in 
the final 3D reconstruction.  
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Figure 9. (A1-C1) Three selected serial images from an SBF-SEM                         
low-magnification image stack. (A2-C2) Colored areas represent some of the 
structures that were selected and manually traced in A1-C1, respectively, for the 
subsequent 3D reconstruction. (D1-D3) Three snapshots of the video showing the 
3D reconstruction: (D1) Two adjacent endothelial cells (ec1 and ec2) can be 
observed. Image B1 is superimposed on the reconstruction. (D2) A pericyte 
rendering is added to the reconstruction. (D3) The complete 3D reconstruction of 
the BBB segment, which includes the renderings of the two adjacent endothelial 
cells, the pericyte and two astrocytic endfeet (ae1 and ae2). Ec: endothelial cell;                 
p: pericyte; ae: astrocytic endfeet. Scale bar: 5 µm [adapted from 25]. 
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Figure 10. (A1-A6) Six selected serial images from an SBF-SEM high-magnification 
image stack. Arrows indicate the same vesicle sectioned on different planes. (B3-B6) 
Original insets from A3 and A6, respectively, in which the brightness and contrast 
have been modified to enhance visualization of the AuNPs. (D3 and D6) Images 
corresponding, respectively, to the insets from A3 and A6 that were obtained after 
applying the process of binarization, which permits to localize the AuNPs. (E1 and 
F1) Representative images of the 3D reconstruction of the SBF-SEM                            
high-magnification image stack that contains images A1-A6. AuNPs are represented 
as green spheres. Blue regions are the endothelial vesicles. bm: basal lamina;                
lum: lumen of the capillary. (E2 and F2) Insets from E1 and F1, respectively. Arrow 
in E2 indicates some AuNPs that have lost the connection with the vesicular 
membrane, while in F2 it shows some ones in which the connection is maintained. 
Scale bar: 2 µm [adapted from 25]. 
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 Thus, this level of magnification and this strategy allowed for reliable 
3D reconstructions in which the structures of the BBB, such as the basal 
lamina of the endothelium and the vesicles located in the BCECs, as well 
as the precise location of the AuNPs could be visualized simultaneously 
(Figure 10). 
 Regarding the shape of the vesicles, the 3D reconstruction allowed us 
to observe that although some of the AuNP-containing vesicles present a 
spherical or ellipsoidal form, they are often branched structures with 
irregular shapes, which sometimes even seem to merge with each other 
forming a complex endosomal network. As can be observed in Figure 10, 
some vesicles that show a spherical or ellipsoidal shape in a 2D plane can 
be considered part of a complex and irregular when subsequent sections 
are analyzed as a whole 3D structure. 
 We can conclude from this work that low-magnification imaging 
permits acquiring images of a large field of view and monitoring of 
relatively long capillary segments (more than 10 µm long), so that results 
appropriate for the identification and 3D reconstruction of cellular 
elements and some subcellular elements as nuclei. However, this resolution 
was too low for clear identification of the AuNPs. This led us to increase 
the level of magnification and re-establish the setting parameters for the 
SBF-SEM system. A higher accelerating voltage allowed the acquisition of 
higher magnification images, with sufficient resolution for AuNP 
visualization. We therefore achieved the goal of 3D reconstructing BBB 
segments and AuNP-containing vesicles, as well as precisely localizing the 
AuNPs within the cellular structures. We observed that the vesicles 
containing AuNPs are often branched structures with irregular shapes, 
which sometimes even seem to merge with each other forming a complex 
endosomal network. Moreover, we applied an innovative method by which 
the AuNPs were replaced by 3D spheres of similar size at the exact same 




 Altogether, the different studies exposed in the present work, allowed 
us to clarify some doubtful aspects concerning the transport of drugs 
across the BBB using RMT and anti-TfR mAbs. These aspects, which are 
summarized in Figure 11, permit to conclude that: 
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1. The 8D3 antibody is capable of recognizing and binding to the TfR 
present in the luminal membrane of brain capillary endothelial cells 
following in vivo administration. 
2. The 8D3 antibody is internalized inside the brain capillary endothelial 
cells after its binding to the TfR. 
3. The 8D3 antibody is able to trigger the internalization of the cargo 
which is conjugated to, overcoming the first obstacle in the transport 
across the brain capillary endothelial cells. 
4. The internalized cargo can vary in size and nature, ranging from 
proteins like the Fab’ fragments of antibodies to larger particles like 
AuNPs measuring 20 nm in diameter. 
5. The internalization of 8D3 and its cargo is produced by a                  
clathrin-dependent endocytosis process. 
6. Most of the resulting endocytic vesicles undergo a process of fusion, 
maturation and reorganization in which the 8D3-cargo complexes that 
are inside them progressively accumulate in endosomal networks of 
great complexity. 
7. During the processing of these vesicles the interaction between TfR, 
8D3 and/or cargo is lost. 
8. Nonetheless, some endocytic vesicles containing the 8D3-cargo 
complexes complete transcytosis. 
9. These vesicles fuse with the basolateral membrane and open up to the 
basal lamina. 
10. When fused with the basolateral membrane, the 8D3-cargo complexes 
become exposed to the basal lamina.  
11. Exposed 8D3-cargo complexes remain attached to the TfR and fail to 
go beyond the basal lamina.  
12. In order to facilitate the cargo liberation to the brain parenchyma, it is 
necessary to modify and optimize the linkages between the 8D3 and 
the cargo and/or the linkage between the 8D3 and the TfR. 
13. Although some improvements at the design level of the constructs are 
needed, the use of the RMT system and mAbs directed against 
transcytosis receptors is a strategy with great potential for transporting 
drugs through the BBB. 
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Figure 11. State of the art of both the transport of drugs across the BBB using                 




 This work is a summary of the doctorate thesis of Itsaso Cabezón, 
carried out in the Blood Brain Barrier Research Group from the Universitat 
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Abstract. The principal aim of this work was to optimize and apply a 
zebrafish experimental model for the screening of anti-inflammatory 
substances present in the Mediterranean diet. The zebrafish is an 
organism widely used in various fields of experimental biology. The 
inflammation is easily inducible, reproducible and visualized in their 
early stages of development. Specifically, the migration of neutrophils 
to the injured caudal fin, one of the first steps of the inflammatory 
response, is quantitatively measured by image analysis. The                   
anti-inflammatory effect of natural compounds can be evaluated as a 
decrease of migration. Adverse effects triggered by inflammation are 
mainly mediated by reactive oxygen species. The anti-oxidant activity 
of compounds was evaluated in zebrafish embryo measuring their 
protective effect against tert-butyl hydroperoxide toxicity. Several 
phenolic compounds have been assayed. Our results showed that the 
compounds with the greatest decrease on neutrophil migration were 
chlorogenic acid and cyanidin. The activity of these two polyphenols 
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was quite similar to that observed with anti-inflammatory drugs (indomethacin, 
piroxicam) and NADPH oxidase inhibitor compounds (dibenzoidolium, apocynin). The 




       
      Nutrition is one of the main determinants of health. Multiple studies 
show that a balanced diet contributes to the prevention of numerous 
diseases. Specifically, the so-called "Mediterranean diet" has been 
associated with benefits in the prevention of many of the most prevalent 
chronic diseases in Western societies; it is known that the Mediterranean 
diet provides important dietary components such as carotenoids and 
phenolic compounds, which can contribute to reduce the risk of developing 
different pathologies [1].  
 Many of these chronic diseases (cardiovascular, metabolic, 
neurodegenerative) have an important component of inflammatory type in 
their etiology and pathological mechanism. Inflammation arises as a 
response of the body's immune system to cellular and tissue damage, and 
involves a cellular component and a chemical oxidative component. The 
cellular component involves the migration of leukocytes, mainly 
neutrophils, from the blood vessels to the injured tissue, attracted by 
several molecular factors liberated by the damaged cells and by the tissue 
resident macrophages. Once the leukocytes reach the site of the injury, a 
series of processes are triggered that include the formation of free radicals 
and the degradation of phospholipids to arachidonic acid (AA) by the 
action of phospholipases; arachidonic acid is metabolized by the 
cyclooxygenase or lipoxygenase pathway, thus producing prostaglandins, 
leukotrienes and thromboxane, inflammatory mediators necessary in the 
inflammation process [2]. Adverse effects of inflammation are mainly 
mediated by cytokines, proteases and oxygen species released by immune 
cells [3]. Therefore, the migration and activation of immune cells must be 
finely controlled because an excess of activity can cause additional tissue 
damage. 
 Neutrophils play a main role in the first steps of inflammation. They 
are the leading cells in host defense responses. The early recruitment is 
guided by tissue damage-associated molecular patterns (DAMPs) 
recognized by specific Toll-like receptors. One of these signal molecules is 
hydrogen peroxide generated by specific NADPH oxidases of injured 
epithelial cells. For more sustained recruitment, additional long-range 
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signals are activated, mainly chemokines of the CXCL8 family. These 
chemokines are produced both by immune cells (neutrophils, macrophages, 
T-cells) and tissue endothelial and epithelial cells. Lipids derived from 
arachidonic acid are also strong inducers of neutrophil chemotaxis. 
 Neutrophils are difficult cells to manipulate, therefore a series of 
techniques are used to understand their biology. Among the models used to 
investigate the biology of neutrophils are purified human neutrophils, 
neutrophil cell lines, murine models and zebrafish. In the zebrafish larvae 
is possible to study the migration of neutrophils in response to a tissue 
injury in the whole organism environment [4]. 
 Like mammals, teleost fishes possess several types of granulocytes and 
a separate lineage of macrophages. The most abundant granulocyte in the 
zebrafish is the neutrophil, which is characterized by having a segmented 
multi-lobed nucleus (2-3 lobes). This cell is similar to the human 
neutrophil, which also has a nucleus of multiple lobes and a heterophilic 
cytoplasm. As the neutrophil matures, so do its granules, expressing and 
accumulating several enzymes necessary for its function including 
myeloperoxidase. Polymorphonuclear neutrophils are the leukocyte 
dominant in zebrafish larvae at 4 days post fertilization (dpf), and in adult 
mammals [5].  
 Diet plays an important role in maintaining an optimal immune 
response, so that deficient intake can have negative consequences on the 
immune status and susceptibility of the organism to a wide variety of 
pathologies. The mechanisms implicated could be mediated by specific 
regulatory effects on the cellular response, or by an unspecific 
“antioxidant” action [6]. The present study is focused on investigating the 
application of a zebrafish larvae model for the screening of natural 
components present in the Mediterranean diet with possible                          
anti-inflammatory activity. The zebrafish is an organism widely used in 
various fields of experimental biology. This animal model has multiple 
advantages such as high fecundity, small size, low maintenance cost, high 
throughput, rapid extra uterine development and the optical transparency 
of embryos and larvae. In addition, the exposure needs small amounts 
dissolved in the surrounding medium and compounds are absorbed through 
the gastrointestinal tract or through the skin, which allows a rapid 
evaluation of pharmacological or toxicological activity in vivo [7-10]. 
 Two types of assays were developed and applied. In the first assay, the 
capacity of the substance to prevent the migration on neutrophils was 
measured. In the second assay, the in vivo “antioxidant” activity was 
evaluated measuring the protective effects against an oxidative stressor. 
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1. Material and methods 
 
Obtaining zebrafish larvae 
 
 Adult wild type zebrafish were kept under standardized conditions. Eggs 
were collected cleaned and selected. Fertilized embryos were treated                       
with standardized water, according to ISO 7346-1 and 7346-2                    
(2mM CaCl2.2H2O, 0.5mM MgSO4.7H2O, 0.75mM NaHCO3, 0.07mM KCl). 




 Natural compounds and anti-inflammatory drugs (Sigma Aldrich) were 
dissolved in dimethyl sulfoxide (DMSO). From the stock solution, serial 
dilutions were made in Danieau's 0.3X medium (17.4 mM NaCl, 0.23 mM KCl, 
0.12 mM MgSO4.7H2O, 0.18 mM Ca(NO3)2, 1.5 mM HEPES, pH 6.5) that 
do not contain more than 1% (v / v) of DMSO if used in larvae or 0.1% if 
used in embryo experiments.  
 
Neutrophil migration assay 
 
 The neutrophil migration assay is based on the model described by 
Cordero-Maldonado et al. (2013) [11]. Zebrafish larvae of 4 dpf previously 
depigmented with 0.2 mM N-phenylthiourea (PTU) were used. 
Inflammation was induced by means of an injury in the tail fin and 
potentiated with the addition of lipopolysaccharide (LPS) 10μg / mL to the 
medium. Exposure to compounds was carried out for eight hours. First a       
pre-exposure of one hour was carried out, before tail fin cutting. 
Subsequently, larvae were exposed to the compound and LPS during                  
7 hours. Larvae were anesthetized and stained with Leucognost pox kit 
(VWR) following the instructions of the manufacturer. Neutrophils were 
stained since all the mature cells of the neutrophilic line are positive for 
myeloperoxidase activity. The tests were carried out in triplicate with larvae 
coming from different spawn with a whole minimum of 20-25 larvae per 
compound. Each test was compared with its own negative control to correct 
the model variability. 
 Stained cells were observed in the area of the lesion. The area covered 
by the stained cells in a selected region of the tail was used as the 
quantitative measurement of migration. A Nikon eclipse TS100 microscope 
was used to capture the images with a 10X magnification. The analysis of 
images was done with the program ImageJ. It consisted of the following 
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phases: first a single image was obtained from three images captured with 
different focus planes. Then the contrast of the image was increased 
applying an exponential transformation. A threshold was applied to 
eliminate the background and saturate the selected signal. Finally, the 
integrated intensity in a standardized region of the zebrafish tail was 
measured as shown in Figure 1. Since the signal was saturated, the intensity 
measured was proportional to the stained area. 
 
Antioxidant activity assay 
 
 The protective capacity against oxidative stress in the whole organism 
was evaluated in zebrafish embryos. Embryos were exposed from 2 to 26 
hours post fertilization (hpf) to the assayed compound or to solvent control 
medium. Afterwards, the medium was changed and embryos were exposed 
to several concentrations of tert-butyl hydroperoxide (tBOOH) (26-50 hpf) 
to induce oxidative stress. At 50 hpf the medium was changed to standard 
Danieau's 0.3X medium (Fig. 2). At 50 and 72 hpf the lethality and the 
presence of malformations was assessed and quantified following the 
procedure previously described by Teixidó et al (2013) [12]. The percentage 
of lethality and of dysmorphogenesis was calculated per compound at every 
tested concentration, and the concentration-response curves for these effects 
were plotted. From these curves the concentration of tBOOH which 
produced mortality to 50% of the embryos (lethal concentration 50, LC50) 
and the concentration at which 50% of the embryos presented at least one 
dysmorphogenic feature (effective concentration 50 for dysmorphogenesis, 
EC50) were calculated. The protective activity of the compounds was 
evaluated measuring the shift to the right of the lethality-tBOOH 
concentration and malformation-tBOOH concentration curves relative to the 
solvent control. The tests were carried out in triplicate with embryos coming 
from different spawn with a whole minimum of 25-30 embryos per 
compound and tBOOH concentration. 
                              
Statistical analysis 
            
 The results were expressed as the mean ± standard error of the mean 
(SEM). They were analyzed with the Graph Pad 7.02 Software Inc. program 
with a two-way ANOVA variance analysis and Bonferroni multiple 
comparison test. The results are shown as a percentage, where the controls 
correspond to 100% of neutrophil migration. In all cases, statistically 
significant differences are considered at three levels of significance,                                                                         
* p <0.05; ** p <0.01; *** p <0.001. 
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     A   B   C 
 
Figure 1. A) Images of zebrafish larvae showing cells with peroxidase positive 
staining captured with three different focus. B) Image before and after threshold 




   
Figure 2. Experimental design of the antioxidant activity assay. Exposure to an 
antioxidant modulator protects from the toxicity induced by tBOOH. Shifts to the 
right of the effect (lethality or malformation index) vs concentration curve of tBOOH 
are observed. 
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Ethical statement 
 
 All procedures with zebrafish, larvae and embryos have been authorized 
by the Ethical Committee of Animal Experimentation of the University of 
Barcelona (protocol 7971 of the Department of Agriculture and Fishing of 
the Generalitat de Catalunya). 
 
2. Results and discussion 
 
Development and assessment of the methods 
 
 The capacity of the method to identify substances with anti-inflammatory 
activity was tested with some well-known positive controls, such as 
indomethacin and piroxicam, some non-anti-inflammatory products, such as 
doxepin and amantadine, and with inhibitors of NADPH oxidases such as 




Figure 3. Migration of neutrophils, expressed in percentage of respective control 
(mean ± SEM). Larvae exposed to different anti-inflammatory substances such as 
indomethacin 100μM (Ind), Piroxicam 5μM (Px),  non-anti-inflammatory compounds 
such as doxepin 5 μM (Dox), amantadine 10 μM (Aman) and inhibitors of NADPH 
oxidases such as dibenzoidolium 100 μM (DPI) and Apocynin 100 μM (Apo). 
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 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both isoforms 
of the enzyme cyclooxygenase (COX). The COX-1 isoform is constantly 
expressed in most tissues, while COX-2 can be induced by various stimuli 
such as cytokines, prostaglandins and bacterial products such as 
lipopolysaccharide that contribute to the development of edema, fever and 
redness [13]. Our results of neutrophil migration in zebrafish larvae exposed 
to indomethacin and piroxicam show respectively 28% and 42% migration 
of neutrophils relative to the control. 
 Amantadine is an anti-viral drug generally used to treat and prevent 
influenza type A and without known anti-inflammatory activity. Treated 
larvae do not present significant differences with their control as the 
migration of neutrophils in this case represented 95%. The result is expected, 
since not being anti-inflammatory they have no effect on neutrophil 
migration. However, doxepin, which is an antidepressant drug, produced a 
moderate but significant inhibition of migration. Some studies suggest that 
doxepin has anti-inflammatory effects and is effective to treat atopic 
dermatitis [14].  
 The enzymes NADPH oxidases are dedicated exclusively to the 
production of reactive oxygen species (ROS). During phagocytosis, 
phagocytes activate NADPH oxidases to reduce molecular oxygen to 
superoxide anion, a precursor of microbicide reactive oxygen species (ROS). 
Previous studies suggest that after injury, cells in the wound margin of 
zebrafish larvae rapidly produce hydrogen peroxide (H2O2) that serves as an 
early paracrine signal to leukocytes [15, 16]. The test with DPI showed a 
significant inhibition of migration to 25% of controls. Apocynin, a phenolic 
compound isolated from the medicinal plant Picrorhiza kurroa, was also 
used, which also showed significant inhibition in neutrophil migration. 
Apocynin has been widely used to block the activity of NADPH oxidase          
in vitro [17, 18]. In our case, apocynin showed a 43% migration compared to 
controls. 
 These results suggest that the method could be applied for the 
identification of substances with potential anti-inflammatory activity. 
Significant inhibition of neutrophils migration was observed with substances 
acting at different molecular target (COX and NADPH oxidases) related 
with different chemotactic stimulus.  
 In order to validate the antioxidant activity assay, different compounds 
with well determined antioxidant activity were tested. A pre-exposure to            
N-acetylcysteine, Nω-Nitro L-arginine methyl ester hydrochloride (L-NAME), 
vitamin E, lipoic acid and quercetin resulted in significant shifts to the right 
hand of the lethality and malformation curves (results not shown).   
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Migration of neutrophils in zebrafish larvae exposed to food compounds 
 
 Tomato is among the most representative foods of the Mediterranean 
diet. Tomato derivatives, such as “sofrito” (fried tomato sauce, with onion, 
garlic, olive oil and some other vegetables), is characterized by containing a 
high variety of polyphenolic compounds [19]. We have assayed the activity 
of some of the major components, such as naringenin, oleuropein, rutin, 
cyanidin, chlorogenic acid and apigenin. The results showed that cyanidin  
and chlorogenic acid produce the greatest reduction of neutrophil migration 
(Fig. 4). 
 The putative protective effects of polyphenols on human health have 
been classically attributed to their antioxidant activity. Polyphenols can react 
directly with some reactive species. However it is now generally accepted 
that the direct scavenging of reactive radicals is not the main mechanism                              




Figure 4. Neutrophil migration in larvae exposed to some polyphenols present in 
“sofrito”. Naringenin 20μM (Nar), Oleuropein 150 μM (Ole), Rutin 20 μM (Ru), 
Cyanidin 20 μM (Cia), Chlorogenic acid 20 μM (Ac.Cl)  and Apigenin 20 μM (Api). 
Data of each treated group is compared with its respective control and the percentage 
of migration is represented.  
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these mechanisms, several are directly related to potential anti-inflammatory  
effects. Inhibition of inflammasome activation and NF-kB inflammatory 
pathway, stimulation of the Nrf2 signalling pathway, inhibition of NADPH 
oxidases and COX have been demonstrated for some specific polyphenols 
[3, 5, 20].  
 Cyanidin is a flavonoid that belongs to the anthocyanins group. 
Anthocyanins are water-soluble pigments present in many fruits and 
vegetables. Some studies demonstrated that oral administration to rats of 
cyanidin-3-glucoside (C3G) attenuates the inflammatory response through 
a decrease in the expression of inducible nitric oxide synthase (iNOS) and 
a suppression of pro inflammatory cytokine production [21]. 
 Chlorogenic acid is a phenolic compound, very abundant in coffee, 
where it represents 98% of the total phenolic content (Martini et al, 2016). 




Figure 5. Neutrophil migration in larvae exposed to some carotenoid compounds 
present in “sofrito”: Lycopene 20 μM (Lic), β-Carotene 25 μM (βC) and Astaxanthin 
20 μM (Ast). 
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in many types of seeds and fruits such as sunflower seeds and blueberries. 
A lower content of chlorogenic acid has also been detected in potatoes, 
tomatoes, apples, pears and aubergines, but consumption of these sources 
represents 5 to 10% of the chlorogenic acid from the coffee source.               
Tajik et al, [22] showed that, in addition to its antioxidant and                          
anti-inflammatory effects, chlorogenic acid is capable of exerting essential 
functions in the regulation of glucose and lipid metabolism, as well as in 
the disorders related to diabetes, cardiovascular disease, obesity and 
cancer. 
 Carotenoid compounds intake is high in the Mediterranean diet 
because they are present in multiple highly consumed foods as tomato and 
carrots. Two of the most abundant bioactive carotenoid pigments are 
lycopene and β-carotene. The strong antioxidant effects and other 
beneficial effects in vitro and in vivo of the carotenes are associated with 
their capacity to act as free radical scavengers. Carotenoids are pigments 
responsible for the color of fruits, flowers and leaves. Lycopene is 
lipophilic, red and is present in ripe tomatoes, the orange color of carrots is 
caused by β-carotene and the pink / red color is due to astaxanthin [23]. 
Most research on the health effects of tomato intake and tomato products is 
concentrated in lycopene; its health benefits have been studied especially 
in the prevention of chronic inflammatory diseases, cancer and 
cardiovascular problems [24, 25]. Our results (Fig. 5) show a moderate 
inhibitory activity on the neutrophil migration. 
 
Antioxidant protective effects 
 
 In most of the cases, pre-exposure to the studied compounds produced 
a significant drift of the concentration-response curves of lethality and 
dysmorphogenesis to higher concentrations of tBOOH (Fig. 6; Table 1). 
The effect in lethality is in general more evident, in part by the higher 
variability of the morphologic effects. 
 It is surprising the lack of effect of resveratrol and EGCG, two of the 
most reputed health promoting polyphenols. These results could be 
explained by a limited bioavailability. However, previous results showed 
that polyphenols are well absorbed by zebrafish embryo from the water 
media [26]. On the contrary, the reason of the lack of effect could be an 
excessive concentration that could yield to a pro-oxidant effect.  
 





Figure 6. Concentration-response curves of lethality and dysmorphogenesis induced 
by tBOOH exposure in zebrafish embryo. In the case of pre-exposure to rutin 10 µM, 
the lethality curve shows a significant shift to the right side, indicating a protective 
anti-oxidant effect. The effect on dysmorphogenesis is less clear but a significant 
decrease of the slope is observed. 
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Table 1. Effect of some polyphenols on the lethality and morphologic abnormalities 
induced by tBOOH in zebrafish embryos. AOX: antioxidant protective effect;                
INC: the compound increases the adverse effect; NE: no significant effect observed. 
 
Compound 













Naringenin 20 µM 2.17 3.48 AOX 1.78 1.80 NE 
Oleuropein 15 µM 2.17 2.65 AOX 1.78 1.85 NE 
Rutin 10 µM 2.17 3.68 AOX 1.78 1.86 AOX 
Cyanidin 20 µM 2.17 3.23 AOX 1.78 1.54 INC 
Clorogenic Ac. 20 µM  2.17 2.59 AOX 1.78 1.90 AOX 
Apigenin 10 µM 2.17 3.35 AOX 1.78 2.00 AOX 
Resveratrol 20 µM 2.71 2.61 NE 2.37 1.86 INC 
Curcumin 10 µM 2.71 3.20 AOX 2.37 3.02 AOX 




 A method for the measurement of neutrophil migration in a whole 
organism in zebrafish larvae has been adapted and optimized. The method 
has been proven reliable and repetitive, although due to the variability of the 
individual response, the use of a large number of larvae and at least three 
replicates with different spawn are required. The quantification of migration, 
by means of image analysis, is reproducible and objective. By means of this 
established model, the anti-inflammatory activity of a selection of 
polyphenols and carotenoids of the Mediterranean diet has been studied. 
 A method for the assessment of antioxidant activity in a whole organism 
has been developed and applied to a series of natural polyphenols. The 
quantification of lethality and dysmorphogenesis is easy and reproducible. 
The protection against the in vivo effects of oxidative stress can be assessed 
independently of the actual mechanism of “antioxidants” action. 
 These methods can be applied to food extracts and can be useful as 
screening tests for the identification of fractions and individual compounds 
with potential anti-inflammatory and antioxidant activity. Additional work is 
necessary in order to assess the concentration-effect relationships of the   
anti-inflammatory and antioxidant activities of natural food compounds. 
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and Hysterothylacium (Rhaphidascarididae) 
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Abstract. The presence of ascaridoid nematodes in commonly 
consumed fish constitutes an important health risk for humans            
as well as an economic problem for fisheries. Here, information is 
provided on the taxonomic status of the representative                     
“anisakid-related” species of the families Anisakidae and 
Raphidascarididae. These parasites have a worldwide marine 
geographical distribution, mainly related to the presence of the 
vertebrate hosts involved in their life cycle. Morphological and 
molecular methods currently used for specific characterization of 
larval and adult nematode specimens are analysed and discussed. 
This study is focused on the taxonomy and parasite-host distribution 
of species of the genera Anisakis and Hysterothylacium from the 
North-East Atlantic Ocean and Mediterranean Sea regions. 
              
1. Introduction 
       
      In the last four decades fish consumption has nearly doubled 
worldwide and global fish production, including aquaculture and wild-catch  
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fisheries, has increased by many tons to meet the growing market demands 
[1]. Some of the most habitually consumed fish species are at risk of 
carrying zoonotic parasites, which can cause economic and sanitary 
problems [2]. In this context, anisakids that include fish in their life cycle 
have been ranked by the European Food Safety Authority [3] as a 
“biological hazard” of the highest importance in seafood products [2]. 
Species of the genera Contracaecum and particularly Anisakis and 
Pseudoterranova have been associated with the fishborne disease 
anisakiosis/anisakidosis, which produces both gastric and allergic reactions 
[4]. Other “anisakid-related” nematodes, such as Hysterothylacium species 
of the family Rhaphidascarididae, although considered non-pathogenic, are 
associated with allergic processes in humans [5] and human infection has 
also been reported [6]. Infection with Hysterothylacium can affect the 
growth rate and health of the fish hosts, making them more vulnerable to 
diseases and even resulting in mortalities [7,8]. 
 Improving taxonomic descriptions for specific identification will shed 
light on the life cycle and geographical distribution of these nematodes, and 
help understand their epidemiological, biological and ecological patterns [9]. 
  
1.1. Taxonomical classification  
  
 The taxonomic status of fish-associated ascaridoid genera with 
zoonotical potential is as follows [10,11,12]: 
 
Phylum:   Nematoda Rudolphi, 1808 
Class:   Secernentea Chitwood, 1958 
Order:   Ascaridida Skrjabin & Schultz, 1940 
Superfamily:  Ascaridoidea Baird, 1853 
Family:   Anisakidae Raillet & Henry, 1912 
Subfamily:  Anisakinae Raillet & Henry, 1912 
Genus:   Anisakis Dujardin, 1845 
Genus:   Pseudoterranova Mozgovoi, 1951 
Subfamily:  Contracaecinae Mozgovoi & Shakhmatova, 1971 
Genus:   Contracaecum Raillet & Henry, 1912 
Family:   Raphidascarididae Hartwich, 1954 
Subfamily:  Raphidascaridinae Hartwich, 1954 
Genus:   Hysterothylacium Ward & Magath, 1917 
  
 The evolutionary taxonomy of the superfamily Ascaridoidea is very 
uncertain, largely because of the great variation in morphological features 
and life cycle patterns among different species [10,13]. Most evolutionary 
hypotheses for ascaridoids were developed prior to the widespread use of 
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molecular techniques and cladistic analysis, and were typically based on the 
variation in one or a few key morphological structures or life history features 
[11].  
 In the last fifty years the systematics and classification of “anisakid-
related” species has been much discussed. For example, some authors 
maintain that the four genera Anisakis, Pseudoterranova, Contracaecum and 
Hysterothylacium should be included in the family Anisakidae, with 
Anisakinae, Contracaecinae and Rhaphidascaridinae reduced to subfamilies 
[14,15,16,17,18], whereas others consider the subfamily Raphidascaridinae, 
which includes the Hysterothylacium species, to be an independent family 
taxon, the Raphidascarididae [10,11,12,19,20].  
 Despite these unresolved issues, no approach integrating both 
morphological and molecular tools has attempted to assess the specific 
classification of anisakid nematodes or the systematic importance of their 
features [12]. However, recent phylogenetic studies based on numerous 
representatives of anisakid nematodes have revealed three main clades that 
correspond to two subfamilies of Anisakidae, Anisakinae (which includes 
the Anisakis and Pseudoterranova genera among others) and Contracaecinae 
(which includes the Contracaecum among others), and one other clade 
corresponding to the family Raphidascarididae, which includes the 
Hysterothylacium genus [2,12].  
 The lack of available molecular and well-presented morphological data 
for “anisakid-related” nematodes makes it difficult to search for patterns that 
may resolve their phylogenetic lineages and shed light on their relationships 
[12].  
 
1.2. Life cycle  
  
 Anisakid species mostly parasitize the digestive tract of marine 
mammals and use teleost fish as paratenic/transfer hosts for their infesting 
larvae. The most representative life cycle of these nematodes is that of 
Anisakis simplex represented in Fig. 1. The life cycle is as follows: 
 
 L1 eggs are released into water through definitive host faeces, where the larval 
maturation process L1-L3 takes place in 20-27 days at 5-7ºC. 
 Immature L3 hatch and are consumed by the intermediate host, mostly euphasid 
crustaceans, in which L3 evolve. 
 Sea fish and cephalopods ingesting parasitized crustaceans act as 
paratenic/transfer hosts, harbouring the infesting L3. 
 When final hosts feed on parasitized fish or cephalopods, L3 evolves into L4  
and finally the adult form, the life cycle ending with egg production by the female.  




Figure 1. Life cycle of Anisakis simplex [4]. 
 
These hosts can also be infested by direct consumption of the intermediate 
crustacean host. 
 Humans eating raw parasitized fish can act as an accidental host, in which L3 
cannot develop to the adult stage. 
 
 In the life cycle of the rhapidascarid Hysterothylacium cold-blood 
organisms like fish, mainly gadiform, act as definitive hosts [21]. Many 
species of this genus can evolve in marine and freshwater ecosystems in 
which fish occupying a low place in the food chain, such as anchovy or 
horse mackerel, usually act as intermediate/paratenic hosts, whereas large 
predatory fish are the definitive hosts, harbouring the adult forms [22,23].  
 
1.3. Sanitary and commercial interest  
  
 The main food-borne zoonoses associated with the consumption of 
fishery products are mainly attributable to trematodes, cestodes and 
nematodes. Among the latter, anisakids are the most important parasites 
from a sanitary point of view, since they are capable of inducing 
anisakiosis/anisakidosis in humans [24]. Transmission occurs when humans 
eat raw or marinated fish parasitized with anisakid larvae L3. Most larvae 
are located in the visceral cavity but can also be present in the flesh 
surrounding this cavity and even deeper within the dorsal part of the fish, 
thus representing a major consumer health risk [2].  
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 The disease can evolve with different symptomatology [25]. In gastric 
anisakidosis, larvae stick to the wall of the stomach and cause abdominal 
pain, nausea and vomiting 6-12 hours after ingestion. It usually remits 
spontaneously but sometimes mechanical extraction by endoscopy is 
necessary. Intestinal anisakidosis occurs when larvae stick to the thin 
intestinal wall, which usually happens 48-72 hours after ingestion and can 
provoke serious inflammatory reactions, sometimes requiring surgical 
extraction. Gastric and intestinal symptoms can be combined in                     
gastro-intestinal anisakidosis.  
 Anisakidosis can also be manifested by allergic reactions, usually 
provoking urticaria or angioedema, and in some severe cases causing 
anaphylactic shock [25]. Some Anisakis species may cause a combination of 
gastric and allergic anisakidosis known as gastro-allergic anisakidosis [2,25].   
 This fishborne pathology can be an important public health problem in 
countries where raw fish is habitually consumed, as occurs on the Eastern 
coast of Asia. The aetiological agents in 90% of documented clinical cases 
worldwide are Anisakis simplex (sensu stricto), Anisakis pegreffii and 
Pseudoterranova decipiens [26]. Nevertheless, studies on the zoonotic 
potential of these nematodes should be extended, since human cases of 
anisakidosis are most likely underreported, probably due to unspecific 
symptoms associated with acute and chronic infections [2]. 
 Furthermore, “anisakid-related” nematodes can entail economic losses 
for the fish industry, involving both wild and farmed fish [2]. When present 
in fish intended for consumption, these parasites have a considerable  
quality-reducing effect due to their unappealing appearance [27], so heavily 
infected fish have no commercial value [28].  
  
1.4. Identification methods   
 
 Accurate identification at the species level is very important to 
understand epidemiological, biological, and ecological patterns [2,18]. 
Morphological methods are useful but are often insufficient for specific 
identification. New molecular methods have provided solid information for 




 Species identification in Anisakidae and Rhaphidascarididae has 
traditionally been complicated due to a lack of differentiating morphological 
features, particularly in larval stages. In adult worms, the morphological characters 
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Figure 2. Main morphological differences at the genus level of third stage larvae L3 
in “anisakid-related” nematodes [21]. 
 
with taxonomic interest are the ventriculus shape; the form of lips; the length 
and shape of spicules and postanal papillae in males; and the position of the 
vulva in females [29,30]. The main morphological taxonomic characters of 
third stage larvae L3 are the structures of the anterior part of digestive tract 
(oesophagus, ventricle, ventricle appendix intestinal caecum); the anatomical 
oral tooth; the position of the excretory pore; the distance of the nerve ring to 
the apical end (Fig. 2), and the caudal morphology, mainly the 
presence/absence of a caudal spine or mucron [21,31,32].  Hysterothylacium 
species are usually found in fish as fourth stage larvae L4,  which can be 
characterized and differentiated mainly by the presence of labia, the absence 
of a tooth, and the presence of a cluster of spines at the caudal end [33]. 
 
Molecular methods 
   
 The first molecular method used in the study of anisakid genetics was 
Multilocus Allozyme Electrophoresis (MAE) (19-24 enzyme loci), which 
revealed the existence of high genetic heterogeneity within Anisakis, 
Pseudoterranova and Contracaecum and increased the diversity of species 
included in these genera. This technique allowed the genetic characterization 
of several anisakid species: it estimated their genetic differentiation, 
established their genetic relationships and identified their larval stages 
without morphological characters [9].  
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 The introduction of polymerase chain reaction (PCR) methods 
confirmed the taxonomic characterisation obtained through allozyme 
markers. Among these methods the most used are PCR-RFLP (Restriction 
Length Polymorphism), a polymorphism study of restriction fragments in the 
PCR products of the ITS-DNA region (Fig. 3) [34]; PCR-SSCP (Single 
Strand Conformational Polymorphism), a conformational analysis of simple 
chain polymorphism of PCR-amplified DNA of ITS regions; direct 
sequencing of PCR-amplified DNA of the 28S region (LSU) and the 
complete internal transcribed spacer (ITS-1, 5.8S, ITS-2) of ribosomal DNA; 
and PCR and sequencing  of cytochromoxidase b (mtDNA cytb) and 
mitochondrial cytochromoxidase 2 (mtDNA cox2) [9]. In recent years the 
analysis and sequencing of the partial gene of the small subunit of the 
mitochondrial ribosomal RNA gene (rrnS) and the elongation factor EF1 α-1 
of the nuclear DNA gene have also been used after PCR for differentiation 
[35,36]. 
 The advantage of these PCR techniques is they allow the use of           
alcohol- or formalin-preserved specimens, whereas MAE is limited to frozen 
or fresh individuals. Moreover, PCR-DNA methods have also facilitated the 
study of phylogenetic relationships between anisakid species based on the 
evolutionary lineage concept and have confirmed the existence of sibling 







Figure 3. Molecular identification of Anisakis and Hysterothylacium larvae by              
PCR–RFLP with HinfI (A), HhaI (B) and TaqI (C) restriction enzymes of the ITS 
PCR products and fragment sizes (D). Fragments in bold might be visible in the gel, 
while fragments in italics might not. M: the 2000 bp DNA ladder marker; N: ITS 
PCR products; Pattern 1: A. simplex (s.s.); Pattern 2: A. pegreffii; Pattern 3: 
Recombinant genotype of A. simplex (s.s.) and A. pegreffii; Pattern 4: A. typica; 
Pattern 5: Hysterothylacium spp.; Pattern 6: H. aduncum; Pattern 7: H. fabri; and 
Pattern 8: H. amoyense [34]. 
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 The description of morphospecies, or species complexes, based on 
previously recognized cosmopolitan species (sensu lato), has solved one of the 
major problems in the systematics of anisakid nematodes, namely the 
occurrence of parallelism and convergence of morphological features. This can 
confound the systematic value of morphological criteria and is often associated 
with a high genetic and ecological divergence between the species [9].  
 Genetic/molecular markers used to characterize anisakid species have 
allowed intermediate/paratenic host fish species and definitive host pinnipeds 
and cetaceans from different geographical marine regions to be screened and 
identified [2]. Genetic data can also provide information on ecological and 
evolutionary aspects, such as host preference and host–parasite co-evolutionary 
adaptations, including host–parasite co-phylogenetic processes [2].  
 
2. Parasite and host geographical distribution 
 
 According to a report by the European Food Safety Authority (EFSA) 
(European Food Safety Authority, Panel on Biological Hazards (BIOHAZ), 
2010), no maritime area can be considered free from anisakids. The 
geographical distribution of different anisakid species, as well as 
raphidascaridids, depends on the distribution of their definitive hosts. As a 
wide range of crustaceans, fish and cephalopods can act as intermediary or 
parathenic hosts, the definitive hosts have more influence on the species 
distribution [9].  
  
2.1. Family Anisakidae  
 
 Most documented and studied species of Anisakidae are included in 
Anisakis, Pseudoterranova and Contracaecum genera. Anisakis species are 
distributed around the world, parasitizing cetaceans, mainly whales and 
dolphins. Pseudoterranova and Contracaecum species usually have pinnipeds 
as definitive hosts, which tend to live in cold waters and are usually found in 
the most northern and southern waters of the planet [9]. 
 
Genus Anisakis  
 
 Up to nine different species of the genus Anisakis have been described 
morphologically and molecularly worldwide (Table 1). All these species are 
characterized by distinct diagnostic genetic markers, possess distinct gene 
pools and are reproductively isolated [2].  
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 A. simplex (sensu lato) is a complex of three sibling species including  
A. simplex (s.s.), A. pegreffii and A. berlandi (= A. simplex sp. C), which are 
morphologically non-differentiable [35]. These species parasitize cetaceans, 
mainly delphinids: the two first are distributed worldwide and the latter are  
 
Table 1. Anisakis species and their geographical distribution based on definitive and 
paratenic host sampling (following [9]). 
 
Anisakis species Geographical distribution 
A. simplex (s.s.)* 
North and North-East Atlantic; Bering Sea; South Africa;                    
North-East and North West Pacific   
A. pegreffii* 
Mediterranean Sea; North-East Atlantic; South West Atlantic;  
North West Pacific; New Zealand and South Africa 
A. berlandi* North-East and South Pacific; South Africa and New Zealand 
A. ziphidarum** Central Atlantic; South Africa and Mediterranean Sea 
A. nascettii** 
Central Atlantic; Iberian Atlantic coasts; South Africa and  
New Zealand 
A. physeteris Mediterranean Sea; Central and North East Atlantic 
A. brevispiculata South Africa; Central Atlantic and Iberian Atlantic coasts 
A. paggiae South Africa; Central Atlantic and North-East Atlantic 
A. typica 
Central and South West Atlantic; Mediterranean Sea; China 
Sea and Somali coast 




Figure 4. Geographical distribution of Anisakis, Pseudoterranova, Contracaecum and 
Phocascaris species based on definitive and intermediate/paratenic host sampling [9]. 
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more focalized (Fig. 4) [9]. A. simplex (s.s.) has also been recorded in other 
cetacean families like Balaenopteridae, Monodontideae and Phocoenidae, 
and A. pegreffii in the family Neobalaenidae. A. ziphidarum and A. nascettii 
are sibling species detected in Ziphiidae cetaceans, mainly in warm waters 
and the southern hemisphere, respectively. A. physeteris is a parasite of the 
kogiidid sperm whale and is typical of Mediterreanean and European 
Atlantic waters. A. brevispiculata and A. paggiae have been detected in the 
pygmy sperm whale in North Atlantic and South African marine waters, and 
A. typica in delphinids from warm waters like the Caribbean Sea [9]. 
 
Genus Pseudoterranova  
 
 Eight distinct species of the genus Pseudoterranova, parasitizing a wide 
range of pinnipeds worldwide, have been molecularly recognised [37]. 
Adults of P. decipiens (sensu lato), which are in fact a complex of six 
biological species, are worldwide-distributed parasites of phocid and otariid 
seals. P. decipens (s.s.) has been documented from a wide range of Phocidae 
species and also some Otariidae, mainly in waters of the northern 
hemisphere (Fig. 4). P. krabbei is typical of the North-East Atlantic and has 
been recorded in Phocidae species. P. bulbosa is habitually found in the 
bearded seal and has been registered mainly in northern waters. P. azarasi 
parasitizes a wide range of pinnipeds, including sea lions and seals, mainly 
from northern waters but has also been documented in Japan. P. cattani is 
also a parasite of sea lions but mainly from South Pacific regions. Finally,          
P. decipiens E is a typical parasite of weddell seals and has been reported 
from the Antarctica [9]. The other two recognised species of Pseudoterranova 
are P. kogiae from the pygmy sperm whale, Kogia breviceps and P. ceticola 
from the dwarf sperm whale, K. sima. 
 
Genus Contracaecum  
 
 The genus Contracaecum comprises at least 50 different species that 
parasitize mostly pinnipeds and fish-eating birds in their adult form (Fig. 4). 
The most studied and documented species are those within the C. osculatum 
and C. ogmorhini complexes. The former includes five sibling species that 
usually parasitize Phocidae: C. osculatum A, C. osculatum B and                          
C. osculatum (s.s.), documented in Arctic hosts; and C. osculatum D and                  
C. osculatum E, documented in Antarctic hosts (Fig. 4). The C. ogmorhini 
complex includes two sibling species that mainly parasitize otariid 
pinnipeds: C. ogmorhini (s.s.), documented in the Austral region, and                    
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C. margolisi from the Boreal area. Other Contracaecum species are                      
C. osculatum baicalensis, molecularly differentiated from the C. osculatum 
complex and endemic to the freshwater Lake Baikal (Russia), C. radiatum, 
documented in Antarctic waters, and C. mirounga, registered in Antarctic 
and sub-Antarctic areas [9]. 
 Clustering methods based on allozyme markers showed that the 
Phocanema species, P. phocae and P. cystophorae (Fig. 4), despite 
morphological differences with Contracaecum species, form a clade with the 
Contracaecum species parasitizing seals, suggesting an evolutionary 
hypothesis for the systematic status of these species [9]. 
 
2.2. Family Raphidascarididae  
 
 The family Raphidascarididae includes numerous genera (~13) and their 
species are distributed worldwide, as are their definitive hosts, which 
constitute a wide range of marine and freshwater fish species. 
Hysterothylacium, Raphidascaroides and Raphidascaris are the genera 
comprising most species, Hysterothylacium being the most prevalent in 
many marine ecosystems [8,17,38].  
 
Genus Hysterothylacium   
 
 The genus Hysterothylacium, currently consisting of ~67 species, is 
considered one of the largest of the fish-parasitising ascaridoid genera, with 
worldwide distribution [33,39]. Hysterothylacium species have been 
documented in an extensive range of marine and freshwater fish, which act 
as paratenic or definitive hosts [17]. 
 Among the five most widely distributed species, H. aduncum has been 
detected in many geographical areas, including the Mediterranean Sea, 
North-East Atlantic, North-East Pacific and the Yellow Sea, as well as 
Antarctic waters and New Zealand coasts. H. corrugatum has been recorded 
along North American Atlantic coasts and also the coasts of Ecuador.               
H. cornutum has been reported in the Adriatic Sea as well as the North 
Atlantic and Pacific Oceans. H. fortalezae is found in the Mediterranean Sea, 
the Brazilian Atlantic coasts and the Gulf of Mexico. H. reliquens has been 
registered in Brazil, Canada and Central America Atlantic coasts, Colombian 
Pacific coasts and the Persian Gulf. Finally, H. zenish has been detected 
from the East and South China Sea to the Java Sea, the North-East 
Australian shelf and Namibia coasts [40].  
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 The genetic study of Hysterothylacium species is still ongoing and their 
taxonomical status is not clear. Martín-Sanchez et al. [41] suggest H. fabri, 
frequently detected in the Mediterranean Sea, is a complex of three sibling 
species. As more work is carried out analysing the possible existence of 
sibling species, the distribution of identified species may change.  
      
3. Anisakis spp. 
 
3.1. Morphological and molecular specific identification  
 
 To date, nine species belonging to the genus Anisakis have been 
identified worldwide [35]. The need to correctly identify Anisakis species 
is especially important at the larval level because they are the causative 
agents of anisakidosis, mainly A. simplex (s.s.) and A. pegreffii. 
Morphological taxonomy of Anisakis species has traditionally relied on 
adult specimens, but in the absence of these forms third stage larvae can be 
distinguished in the morphological types I and II, following the criteria of 
Berland [31], which is based mainly on the length of the ventricle and the 
presence/absence of a spine or mucron at the caudal end. Anisakis type I, 
characterized by a long ventricle and the presence of a mucron, includes 
the A. simplex (s.l.) complex, with an oblique ventricle-intestine union, and 
the species A. ziphidarum, A. nascettii and A. typica, with a blunt ventricle-
intestine union (Table 2). Species included in type II are A. physeteris,                  
A. brevispiculata and A. paggiae, whose larvae lack a mucron and have a 
short ventricle; they also tend to be bigger than species of type I.  
 In many cases these morphological differences are insufficient for 
species identification, and molecular approaches are needed. 
Discriminatory morphometric analysis of the main morphological 
characters of larvae of non-differentiable species of the A. simplex 
complex, A. simplex (s.s.) and A. pegreffii, has been suggested as a 
possible method of species differentiation [42]. Ventricle length and the 
oesophagus/ventricle length ratio have been proposed as discriminating 
parameters in both L3 and L4, after measuring the total body length, the 
maximum body width, the distance of the nerve ring from the anterior end, 
the length of the oesophagus, the ventricle length and width, the ratio 
between the oesophagus and ventricle length, the tail length and the 
mucron. More morphometric studies of the two sibling species larvae from 
different geographical areas are required to find more discriminatory 
functions of morphological parameters. 
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Figure 5. Phylogenetic clades based on the combined mtDNA cox-2, rrnS rRNA and 
ITS rDNA from sequence data of all characterized species of the genus Anisakis 
(modified from [2]). 
  
 In the specific genetic characterisation of Anisakis species several 
molecular methods have been used, principally allozyme markers, sequence 
analysis of mtDNA cox2 and rrnS, and direct sequencing of nuclear DNA 
such as EF1 α-1, ITS rDNA and PCR-RFLP. Four different phylogenetic 
clades comprising different Anisakis species have been detected by these 
methods [2] (Fig. 5). The first and the second clades include two groups of  
sibling species: A. simplex (s.s.), A. pegreffii and A. berlandi (= A. simplex sp. C); 
and A. ziphidarum and A. nascettii, respectively. The third clade is formed 
by the species A. physeteris, A. brevispiculata and A. paggiae; and the last 
clade, as a separate lineage, includes A. typica [2]. 
 The phylogenetic classification of Anisakis species shows that the six 
species with larvae morphologically characterized as type I are distributed 
in the first, second and fourth clades, whereas the three species whose 
larvae belong to type II are all in the third clade (Table 2). 
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Table 2. Morphological differences of L3 of Anisakis species, related to larval type 
and cladistic classification. 
 
Species 






(Mattiucci et al. 
 2017) [2] 
A. simplex (s.s.)* 
A. pegreffii* 
A. berlandi* 
Presence of mucron, long ventricle.  
Oblique ventricle-intestine union 
          I First clade 
A. ziphidarum** 
A. nascettii** 
Presence of mucron, long ventricle.  
Blunt ventricle-intestine union 
          I Second clade 
A. typica 
Presence of mucron, long ventricle.  
Blunt ventricle-intestine union 
          I Fourth clade 
A. physeteris 
Absence of mucron, short ventricle           II Third clade A. brevispiculata  
A. paggiae 
 
*Sibling species of the complex A. simplex (sensu lato); **sibling species 
   
3.2. Presence of Anisakis species in vertebrate hosts from the 
North-East Atlantic Ocean and Mediterranean Sea 
  
 Regarding fish consumption and anisakidosis risk in the Iberian 
Peninsula, two marine geographical areas are of interest, the North-East 
Atlantic Ocean, corresponding to FAO (Food and Agriculture Organization) 
zones 27.8 and 27.9, and the Mediterranean Sea, corresponding to FAO zone 37. 
Focusing on the Anisakis species distribution in these two maritime zones,  
A. simplex (s.s.) and A. pegreffii are the most detected species, and also the 
most associated with human cases of anisakidosis. A. simplex (s.s.) is the 
most documented species in the North-East Atlantic, its southern limit being 
the Spanish Atlantic coast near Gibraltar and the Alboran Sea, and the 
northern limit the Arctic Sea. This species has not been detected in the 
Mediterranean although it has been registered in the Alboran Sea, 
oceanographically considered part of the Atlantic Ocean. On the other hand, 
A. pegreffii is widely distributed in the Mediterranean Sea and is also 
present, but with less prevalence, in the North-East Atlantic. A. pegreffii 
shares a southern limit with A. simplex (s.s.) of the Spanish coasts, whereas 
its northern limit is the Bay of Biscay, although it has been detected in some 
migratory fish species from more northern waters [2]. 
 Several cetacean species have been documented as definitive hosts for 
A. simplex (s.s.) and A. pegreffii (see Table 3). Although both sibling species  
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Table 3. List of definitive hosts recorded for the species A. simplex (s.s.) and                   
A. pegreffii from the North-East Atlantic and Mediterranean Sea (modified from 
[2,9]). 
 
Definitive host  A. simplex (s.s.)  A. pegreffii  
Cetaceans  
   Balenopteridae 
  
      Balaenoptera acutorostrata NEA - 
  Delphinidae   
     Delphinus delphis NEA M 
     Globicephala melaena NEA NEA, M 
     Lagenorhynchus albirostris NEA - 
     Stenella coeruleoalba NEA M 
     Tursiops truncatus  - M 
  Phocoenidae   
     Phocoena phocoena NEA - 
 
  NEA: North-East Atlantic; M: Mediterranean Sea 
 
can share the same definitive hosts, in the North-East Atlantic A. pegreffii 
has only been documented in one cetacean species, Globicephala melaena, 
while in the Mediterranean it has been reported in other species like 
Delphinus delphis and Stenella coeruleoalba, which are also hosts of                         
A. simplex (s.s.) in the North-East Atlantic [2]. 
 A. simplex (s.s.) and A. pegreffii share and even co-infect a wide range 
of teleost fish species of several families, which act as paratenic hosts (see 
Table 4). Some of these species are habitually consumed fish such as hake 
(Merlucius merlucius), horse mackerel (Trachurus trachurus), blue whiting 
(Micromesistius poutassou), cod (Gadus morhua), anchovy (Engraulis 
encrasicolus), Atlantic mackerel (Scomber scombrus) and squid (e.g. 
Todarodes sagittatus) [2]. A. simplex (s.s.) has also been recorded in three 
squid species of the family Ommastrephidae [2]. 
 In sympatric areas where the sibling species A. simplex (s.s.) and                 
A. pegreffii share cetacean and fish hosts, hybrid specimens between these 
species have been reported [43,44,45,46]. However, the large recovery of 
larval hybrid forms in fish and the rare observation of hybrid adults in 
marine mammals has induced controversy in the taxonomical interpretation 
of these hybrids, becoming an important unresolved issue in Anisakis 
taxonomy [36,47,48]. 
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 Regarding other Anisakis species, according to Mattiucci’s review, three 
species have been detected in the North-East Atlantic and the Mediterranean 
[2,9]. A. physeteris has been documented in the North-East Atlantic from the 
sperm whale Physeter macrocephalus (Physeteridae) and in the 
Mediterranean Sea from Physeter catodon. A. typica has been registered in 
the Mediterranean delphinid Stenella coeruleoalba, and A. paggiae, although 
not recorded in the North-East Atlantic, has been associated with Kogiid 
whales (Kogia breviceps and K. sima) from this area, due to the presence of 
larvae in the deep-sea fish Anoplogaster cornuta, which supports an oceanic 
deep-water life cycle for this species [49]. These three Anisakis species have 
also been detected in different paratenic/fish hosts from the same zones:               
A. physeteris in Trachurus trachurus, Merlucius merlucius, Phycis phycis, 
Physcis blenoides, Scomber scombrus and Xiphias gladius; A. typica in 
Trachurus trachurus, Merlucius merlucius, Phycis phycis and                    
Scomber scombrus; and A. paggiae in Merlucius merlucius [2,9].  
    
4. Hysterothylacium spp. 
 
4.1. Morphological and molecular specific identification  
 
 Hysterothylacium species are potential zoonotic parasites and are the 
most common species of Raphidascarididae, having been reported in a wide 
range of fish [13,50]. The study of adult worms in their fish final hosts is 
essential for a correct specific identity, but is not always available.  
 Morphological larval type description is based on the main 
morphological parameters: the presence/absence of a tooth for L3 or labia 
morphology for L4, the position of the excretory pore, the ventricular 
appendix, the intestinal caecum and the morphology of the tail, with the 
presence/absence of a mucron or a cluster of spines (also called a cactus) as 
shown in Fig. 6. Morphometric analysis of these parameters is also important 
for the larval classification [33]. 
 The attempt to characterize and classify these larvae has been extensive 
in marine teleost fish from the South Pacific (Australia and New Caledonia) 
and the Persian Gulf. Up to sixteen different larval morphotypes have been 
described in these areas, most of them with both a morphological and 
molecular characterization [33,51,52]. Shamsi et al. [33] proposed a key to 
differentiate the several morphotypes present in Australian waters. This key 
needs to be extended to include the new morphotypes described in other 
regions.  
 Each larval morphotype cannot be associated with a single species 
because sometimes the same morphotype presents different genotypes [33],  
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Figure 6. Hysterothylacium morphotypes. Larval type III: a) and b) anterior and 
posterior ends, respectively (scale-bars=0.4 and 0.2 mm, respectively). Larval type 
IV: c) anterior end (scale-bar=0.4 mm), d) labia (scale-bar=0.3 mm) and e–h) 
posterior ends (scale-bar=0.2 mm in e and f and 0.1 mm in g and h). Larval type V: i) 
and j) anterior and posterior ends (scale-bars=0.2 mm). Larval type VI: k) and l) 
anterior and posterior ends (scale-bars=0.4 and 0.2 mm, respectively), excretory pore 
was not visible in this specimen (modified from [33]).   
 
meaning that different species can have similar larval morphology. 
Moreover, larvae can exhibit rather uniform morphology, which is 
completely different from their adult forms [18]. A comparison between 
larval morphology and genetics is needed to specifically identify larval 
morphotypes, the sequencing of ITS-1 and ITS-2 of rDNA after PCR 
amplification of these regions being the most used molecular method for 
this purpose [18,33]. 
 Studies on Hysterothylacium morphotypes from fishes in different 
European marine waters are scarce. In this area Hysterothylacium larvae 
are usually identified based solely on morphological parameters and very 
few studies compare the larval morphology with a proper molecular 
analysis [38,53]. Therefore, more studies are needed to ascertain the 
possible morphotypes present in European marine waters.  
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4.2. Presence of Hysterothylacium species in vertebrate hosts from 
the North-East Atlantic Ocean and Mediterranean Sea  
  
 Within Hysterothylacium species in Mediterranean and North-East 
Atlantic regions, H. aduncum is the most frequently reported in a wide range 
of teleost fish [22,54]. However, H. fabri is typically reported in many 
Mediterranean fish species, sometimes with a higher prevalence than                 
H. aduncum [38,41,55]. As mentioned in section 2.2, while H. aduncum has 
been detected worldwide, for example, in the North-East Pacific and the 
Yellow Sea as well as Antarctica and New Zealand waters, H. fabri has only 
been documented in the South and East China Sea [40].   
 H. aduncum and H. fabri specimens from the Mediterranean and the 
North-East Atlantic have been mostly detected in their larval forms (see 
Table 5) and very few studies have documented their adult form in final fish 
hosts in these regions. Sanmartin-Duran et al. [56] detected adult specimens 
of H. aduncum in Scophthalmus maximus and Conger conger, while 
Mackenzie et al. [54] and Carreras-Aubets et al. [57] reported the adult form 
in Trachurus trachurus and Mullus barbatus, respectively. Adult forms of   
H. fabri have been documented [58] in Mullus surmulentus.  
 Other Hysterothylacium species, including H. corrugatum, H. incurvum 
and H. petteri, have been recorded in swordfish (Xiphias gladius) from the 
Mediterranean Ionic and Tyrrhenian Sea, and the North-East Atlantic Ocean 
[35]. Moreover, some authors have also found H. auctum in the Baltic Sea 
[68], and Gibson [69] lists 13 different Hysterothylacium species in 
European marine waters, including H. aduncum and H. fabri but without 
specifying the region. Regarding the Mediterranean Sea, Bruce et al. [39] 
detected H. fortalezae, without specifying the region, H. cornutum and                         
H. increscens in the Adriatic Sea, H. bifidalatum in the Algerian part of the 




 The present review highlights the importance of improving taxonomic 
descriptions of “anisakid-related” nematode species. Accurate species 
identification and knowledge of their geographical distribution would shed 
light on the epidemiological, biological and ecological patterns of these 
parasites, which are of sanitary and commercial concern. Among 
Anisakidae, Anisakis spp. are the main causative agents of anisakidosis and 
the most widely detected in cetacean definitive hosts worldwide, while 
Pseudoterranova and Contracaecum species have a more reduced 
distribution, mainly in the most northern and southern areas of the planet, 
pinnipeds being their main definitive hosts. 
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 Classification of the genus Hysterothylacium at the family level remains 
controversial, and its inclusion in the family Raphidascarididae is not 
unanimously accepted. In their larval stages, A. simplex (s.l.) and                       
H. aduncum are the most frequently detected species in a wide range of 
commonly consumed fish from European and Spanish marine waters, 
including the North-East Atlantic and Mediterranean. Specific identification 
of these nematodes at larval stages, combining morphological and molecular 
methods, is crucial from an epidemiological point of view, due to the 
existence of morphologically non-differentiable sibling species, such as                
A. simplex (s.s.) and A. pegreffii, both of sanitary importance. The detection 
of hybrids of these two species needs to be followed up by genetic 
characterization studies to ascertain if they are viable hybrids giving rise to 
hybrid adults. Although molecular methods are effective in many cases, 
morphological knowledge of larvae and adults is still important for correct 
identification. It is therefore necessary to undertake studies on Hysterothylacium 
morphotypes in fish from marine European waters for which data remain 
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Abstract. The introduction of high performance thin-layer 
chromatography (HPTLC) for quality control of herbal products, 
using standardised methodology and system suitability tests for the 
qualification of the plates, has improved reproducibility. The use of 
intensity markers implemented by the Ph. Eur. improved the 
description and interpretation of the chromatograms. Quantitative 
information can be retrieved from the electronic images of the 
chromatograms and used for comprehensive HPTLC fingerprinting: a 
single HPTLC analysis gives information on identity, purity and 
content of an herbal drug/preparation/product, simplifying the quality 
control. 
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Introduction 
 
 Herbal products are those that contain herbal drugs, herbal drug 
preparations or their combinations as active ingredients.  
 According to the European Pharmacopoeia (Ph. Eur.) [1], herbal drugs 
are mainly whole, fragmented or broken plants or parts of plants in an 
unprocessed state, usually in dried form but sometimes fresh. The word 
“plant” is here used in the broader sense to also include algae, fungi and 
lichens. Certain exudates that have not been subjected to a specific treatment 
are also considered to be herbal drugs.  
 Herbal drug preparations (or herbal preparations) are homogeneous 
products obtained by subjecting herbal drugs to treatments such as 
extraction, distillation, expression, fractionation, purification, concentration 
or fermentation. They include, for example, extracts, essential oils, 
expressed juices, processed exudates, and herbal drugs that have been 
subjected to size reduction for specific applications, for example herbal 
drugs cut for herbal teas or powdered for encapsulation [1]. 
 In most of the cases herbal products reach the market as medicines or as 
dietary supplements, depending on the region and the regulatory framework 
applied, which have different quality requirements. However, the quality of 
herbal drugs and herbal preparations is the basis for the reproducibility of the 
safety and the efficacy, and should be taken into account in all steps of the 
production process. The chemical complexity of herbal drugs and 
preparations, its variability inherent to its natural origin, the limited 
knowledge of the chemical constituents responsible of the therapeutic 
activity, and the possibility of adulterations and contaminations, make the 
quality control a challenging process [2]. 
 The main objectives of quality control are to certify the identity of the 
herbal drug/preparation/product analysed, its purity concerning possible 
adulterations, falsifications and contaminants, and the strength/content of 
active principles or markers. Quality specifications published in 
Pharmacopoeias, which include analytical methods plus criteria of 
acceptance, are mandatory for medicinal products and can also be followed 
for dietary supplements [3].  
 Identification of herbal drugs and detection of possible adulterations rely 
in macroscopical and microscopical examinations and the analysis by           
thin-layer chromatography (TLC) or high performance thin-layer 
chromatography (HPTLC). In the case of herbal preparations, such as 
extracts, TLC/HPTLC are the preferred techniques and, sometimes, other 
chromatographic techniques, like gas chromatography (GC) in the case of 
essential oils, are used. Content/strength determination is done mainly by 
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high performance liquid chromatography (HPLC) and in certain cases by GC 
or spectrophotometry.  
 Although TLC was very early included in the Pharmacopoeias for the 
analysis of herbal drugs and preparations, significant improvements have 
been achieved by the introduction of HPTLC and the standardisation of the 
methodology. The objective of the present chapter is to introduce to the 
reader the new opportunities opened by these improvements that allow a 
deeper exploitation of HPTLC in the field of quality control of herbals.  
 
1. High performance thin-layer chromatography 
 
 High performance thin-layer chromatography (HPTLC) is a planar 
chromatographic technique resulting from the evolution of the classical       
thin-layer chromatography (TLC), but it goes far beyond the old TLC 
performed on HPTLC plates [4]. Indeed, HPTLC and TLC share the same 
basic principles involved in the separation, which results from the interaction 
of the constituents of the sample with a planar stationary phase, the liquid 
mobile phase and the gas phase produced in the chromatographic chamber. 
Also, they share advantages such as visual results, parallel analysis of 
samples, single use of the plate, rapid results, flexibility and the possibility 
of multiple detection. Some technical differences between HPTLC and TLC, 
concerning the plate, solvent consumption, duration of development and 
sensitivity are shown in Fig. 1. 
 Beyond this differences and similarities, HPTLC is a new concept, 
which primary focuses are reproducibility and separation power. It uses 
well-defined methods, with optimized and standardized parameters, that pass 
a validation process, and give reliable analytical results with good intra- and 
inter-laboratory reproducibility. Instrumentation for HPTLC can be simple to 
sophisticated and allows obtaining traceable digital images and a deeper 
exploitation of the data contained in these images. Moreover, HPTLC is 
GMP friendly [4,5]. 
 Well described sample preparation, well defined layout of the plate 
and volume of application, as well as fully specified chromatographic 
conditions and detection system(s), including not only the composition of 
the mobile phase, but the relative humidity, the use of a saturated, an 
unsaturated or a pre-conditioned chamber, the developing distance, etc. are 
necessary for reproducible results. The use of a method-specific system 
suitability test (SST) on each plate is a key point in order to qualify the 
developed plate, rely on each single analysis and compare analyses done 
on different plates. 
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Figure 1. Some differential characteristics of TLC and HPTLC. 
 
2. Quality of herbal medicinal products, HPTLC and 
Pharmacopoeia 
 
 The active ingredients (herbal drugs and herbal preparations, such as 
extracts or essential oils) of the herbal medicinal products must fulfill the 
quality requirements established in the corresponding regulations, including 
the related Pharmacopoeia. The objective of these specifications is to 
demonstrate identity, purity and content of active principles or markers [2,3]. 
 TLC and, more recently, HPTLC has been traditionally used for proving 
identity of herbal drugs and extracts, as well as for the investigation of the 
presence of possible adulterations or falsifications, which is a key part of 
establishing the purity. In addition, HPTLC is also used, to a lesser extent, for 
the quantification of active principles or markers. The use of TLC/HPTLC for 
checking the identity and purity is mainly based on the visual observation of 
the chromatographic fingerprint, this is the sequence of zones of the 
chromatogram of the sample, taking in account the number, position (RF) and 
color/fluorescence of the zones in one or more detection modes. 
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Detection 1: UV 254 nm 
 
 
Detection 2: NPR + PEG / UV 366 nm 
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 1. Caffeine 3. Rutin 5-13. Mate leaf samples 
 2. Chlorogenic acid 4. Rutin and chlorogenic acid 
 
 
Figure 2. HPTLC chromatograms for identification of mate leaf (Ilex 
paraguariensis A.St.-Hil.) A single analysis with two subsequent  
 
 
Figure 2. HPTLC chromatograms for identification of mate leaf (Ilex paraguariensis 
A.St.-Hil.) A single analysis with two subsequent detections allows the detection of 
caffeine, under UV 254 nm, and polyphenols (caffeoylquinic acids and flavonoids), 
under 366 nm after derivatisation with NPR and PEG. Developing solvent: toluene, 
water, anhydrous formic acid, ethyl formate, (3:6:8:60 V/V/V/V). Plate: HPTLC 
silicagel 60 F254. NPR: Natural product reagent, PEG: Polyethylenglycol 400. 
 
 The possibility of multiple detection gives flexibility to TLC/HPTLC 
and allows detecting compounds of different phytochemical groups in a 
single analysis. Figure 2 shows, as example, the case of mate leaf (Ilex 
paraguariensis A.St.-Hil.), the characteristic constituents of which are 
caffeine and polyphenols, particularly caffeoylquinic acids and flavonoids 
[6]. In a single HPTLC analysis of the samples extracted with methanol, two 
detections are used subsequentially: first, the observation of the developed 
plate under UV light at 254 nm, allowing the detection of caffeine by 
comparison to a reference substance on a separate track, followed by a 
second detection using natural product reagent (NPR) and polyethylenglycol 
400 (PEG) and observation under UV light at 366 nm. This second detection 
system cannot show the presence of caffeine, but detects a series of zones 
due to caffeoylquinic acids and flavonoids characteristic of mate leaf. 
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 HPTLC is also very useful for discriminating close taxa that can be used 
as adulteration or falsification of the desired species. Recently, an optimized 
HPTLC method has been described that distinguishes the roots of 28 
different Angelica taxa and related species belonging to the Apiaceae family, 
including those traditionally used in Europe (e.g. Angelica archangelica L., 
Levisticum officinale W.D.J.Koc) and those traditionally used in Asian 
countries such as Angelica acutiloba (Siebold & Zucc.) Kitag., A. dahurica 
(Hoffm.) Benth. & Hook.f. ex Franch. & Sav., A. gigas Nakai, A. pubescens 
Maxim., A. sinensis (Oliv.) Diels, Ligusticum sinensis Oliv., and Ligusticum 
chuanxiong S.H.Qiu, Y.Q.Zeng, K.Y.Pan, Y.C.Tang & J.M.Xu. [7]. 
 Lavender flower (Lavandula angustifolia Mill.) is an herbal drug used 
mainly as sedative [8], whereas lavandin (Lavandula × intermedia Emeric ex 
Loisel.) is a hybrid between L. angustifolia Mill. and L. latifolia Medik., 
used for the production of essential oils as ingredients of industrial perfume 
and fragrance materials. The essential oils of both lavender flower and 
lavandin flower are characterized by a high content of linalool and linalyl 
acetate. Lavandin has higher biomass and oil yield, but the oil is considered 
of lower quality due to the higher content of 1,8-cineol and camphor [1,9]. 
 The presence of a purple zone in lavadin flower, absent in lavender 
flower, allow an easy differentiation of both species by the HPTLC analysis 
of their toluene extracts, as it is shown in Fig. 3. In addition, the analysis 
clearly discriminates old lavender flowers from the herbal drug harvested in 




Figure 3. HPTLC chromatograms for identification of lavender flower (Lavandula 
angustifolia Mill.) and discrimination of lavandin flower (Lavandula × intermedia 
Emeric ex Loisel.) (see red rectangle). In addition, old samples (one and two years 
old) can also be distinguished from the sample of the current year (see blue 
rectangle). Developing solvent: ethyl acetate, toluene (5:95 V/V). Plate: HPTLC 
silicagel 60 F254. 
HPTLC in quality control of herbal products 125 
 Gas chromatography (GC) is the technique of choice for essential oils, 
due to the volatility of their constituents, mainly mono- and sesquiterpenes. 
However, sometimes, essential oils are adulterated with fatty oils. 
Triglycerides, the major constituents of fatty oils are not volatile and, 
consequently, are not detected in the GC analysis of the essential oil: the GC 
profiles of the pure and adulterated essential oils are similar and the 
adulteration is not detected. HPTLC is able to distinguish between the pure 
and the adulterated oil and, in a second analysis, can give information on the 
fatty oil used as adulterant. As example, Figure 4 shows the case of the 
detection of this type of adulteration in the essential oil of sage                  
(Salvia officinalis L.). 
 According to the EU regulations [10], stability studies are necessary for 
the market authorization of an herbal medicinal product. This is another part of 
the quality requirements where HPTLC has a place. Unless justified, the 
accepted variation in content of constituents with known therapeutic activity 
during the proposed shelf-life is ± 5% of the declared assay value. Whereas 
when constituents with known therapeutic activity are unknown (markers             
are used in this case) the accepted variation is ±10% of the initial assay value.  
 
other constituents of the herbal drug or the herbal preparation should, as far 
as possible, also be demonstrated. The HPTLC fingerprint chromatograms 




GC analysis of the essential oils HPTLC analysis  
for essential oils 
HPTLC analysis  
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Figure 4. Detection of adulteration of sage essential oil with a fatty oil by HPTLC. 
The adulteration is not detected by the analysis of the essential oil by gas 
chromatography (GC), but by HPTLC, where the triglycerides of the fatty oil produce 
a distinctive zone in the chromatogram of the adulterated oil (see red rectangle). The 
HPTLC analysis of the essential oil using a method for fatty oils shows that the fatty 
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Figure 5. HPTLC chromatograms used for a stability study of a combination of herbal 
drugs in capsules. For each time point, left track corresponds to reference solution and 
right track to test solution. 
 
 
Figure 4. Detection of adulteration of sage essential oil with a fatty oil by HPTLC. 
The adulteration is not detected by the analysis of the essential oil by gas 
chromatography (GC), but by HPTLC, where the triglycerides of the fatty oil 
produce a distinctive zone in the chromatogram of the adulterated oil (see red 
rectangle). The HPTLC analysis of the essential oil using a method for fatty oils 
shows that the fatty oil used for the adulteration produces a profile similar to that of 
corn oil. 
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Figure 5. HPTLC chromatograms used for a stability study of a combination of 
herbal drugs in capsules. For each time point, left track corresponds to reference 
solution and right track to test solution. 
 
Nevertheless, since the herbal drug or herbal preparation in its entirety is 
regarded as the active substance, the determination of the stability of the 
constituents with known therapeutic activity or the markers is not considered 
sufficient. The stability of other constituents of the herbal drug or the herbal 
preparation should, as far as possible, also be demonstrated. The HPTLC 
fingerprint chromatograms are appropriate in this case, as it is shown in Fig. 5.  
 
3. Recent improvements in the Pharmacopoeias 
 
 TLC has been included since decades in most of the Pharmacopoeias as 
identification tool for herbal drugs and herbal preparations. However, a 
number of issues have been observed over the years with this traditional use, 
in part due to the technique and in part due to the nature of the herbal 
materials. First, the variability of the chromatograms obtained, partially due 
to the inherent variability of the herbal drugs (differences between batches), 
but also to the lack of intra- and inter-laboratory reproducibility of the 
analysis. Second, the difficulties on the description and interpretation of the 
chromatograms. Over the years, the evolution of the description systems in 
the Ph. Eur. has improved its accuracy by changing from plain text to the use 
of tables. However, it remains a challenge to describe the natural variability 
of an herbal drug in a single description of the TLC/HPTLC fingerprint, 
including the selection of zones to be considered/described and the definition 
of their position, color and intensity in a way that avoids, as far as possible, 
ambiguity in the interpretation. At the end, the qualified person in a 
laboratory has to decide whether the fingerprint of a sample is compliant 
with that described in the pharmacopoeia. Moreover, in most of the cases, 
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the pharmacopoeias do not include any system suitability test for 
qualifying the plate before any interpretation of the chromatograms 
[11,12]. 
 In order to solve these issues, improvements have been implemented in 
several pharmacopoeias, that published new general chapters on the 
analysis of herbal drugs and preparations by HPTLC: the general chapter 
2.8.25 (High-performance thin-layer chromatography of herbal drugs and 
herbal drug preparations) in the 9
th
 edition of the European 
Pharmacopoeia [1] and the general chapters <203> (High-Performance 
Thin-Layer Chromatography Procedure for Identification of Articles of 
Botanical Origin) and <1064> (Identification of Articles of botanical 
origin by High-Performance Thin-layer Chromatography procedure) in 
the USP 38 – NF 33 [13]. 
 The first step for improving reproducibility is the use of HPTLC 
instead TLC, because inter-laboratory trials performed in the framework of 
the Ph. Eur. have demonstrated the higher reproducibility of this technique 
[11,12]. 
 The second step is the standardisation of the methodology. This is the 
use of standard operating procedures (SOP) that include detailed 
descriptions of all relevant parameters, such as preparation of the sample, 
plate setup and handling, sample application (as band), chamber geometry 
and saturation, humidity control, developing distance, derivatisation 
procedure and observation, documentation (as electronic images), and 
evaluation of the chromatograms. The standards used nowadays in the             
Ph. Eur. and the USP are following the recommendations of the HPTLC 
Association (www.hptlc-association.org). The new general chapters of the 
Ph. Eur. and the USP include detailed description of the common part of 
the HPLC methodology, while the specific information regarding each 
method is included in the corresponding individual monograph. 
 The qualification of the plate is a key factor for improving 
reproducibility of the HPTLC analysis. It answers the question: Was the 
HPTLC analysis properly done? Only qualified plates should be used for 
evaluation of results and for comparison of results of different analyses of 
the same herbal drug or preparation, performed in the same or in different 
laboratories. 
 There are different approaches to the qualification of the plate. In the 
USP, it is based on two or more reference substances that have just 
separable RF or (in most cases) a reference extract, for which results should 
match description of colors and position, within a specified range. In the 
HPTLC Association, it is mainly based on reproducible and standardized 
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HPTLC results, with the definition of exact RF values. Finally, in the Ph. 
Eur. a system suitability test (SST) is described in each method and it is 
based on the separation of 2 substances that have similar retardation factors 
(RF values) but that are barely separable under the specified chromatographic 
conditions. An example of selection of a pair of substances for SST is shown 
in Fig. 6 for an analysis of flavonoids and phenolic acids [11]. The SST is 
normally applied on the first track and, in addition to the qualification of the 
plate, it is also used for normalization of the electronic image of the plate. 
 As mentioned earlier, one of the main issues with the traditional use of 
TLC was the description and interpretation of the chromatograms. The 
description has to take into account the sequence and characteristics of the 
zones (number, position, colour and intensity). The interpretation of the 
intensity was highly subjective, because there was not a reference to 
compare with.  In order to improve this situation, the new chapter 2.8.25 of 
the Ph. Eur. has introduced the use of intensity marker. The intensity 
marker is selected from the reference substances used. The reference 
solution (containing the intensity marker) is applied on adjacent tracks at the 
normal concentration and diluted one to four. The intensity marker will give 
different intensities in the two tracks. The intensities of the zones of the 
chromatogram of the test solution are described comparing to these two 
different intensities. The meaning of the descriptors used in the Ph. Eur. is 




Figure 6. Selection of a pair of substances for the system suitability test (SST) in the 
analysis of flavonoids with the developing solvent ethyl acetate, formic acid, water 
(80:10:10 V/V/V/V) on a HPTLC silicagel 60 F254 plate. The pairs of the first two 
tracks are suitable for the SST, and preferable to the pair of compounds of the track 
three, which are very close together. The pairs of the two last tracks are not suitable 
because the two compounds tested are too far from each other. NPR: Natural product 
reagent, PEG: Polyethylenglycol 400. 






Visual intensity description  
Chlorogenic acid (CA) is used as example of intensity marker 
 
Intense zone:  
More intense than CA zone intensity (a) 
Equivalent zone or with no descriptor for intensity: 
Similar in intensity to CA zone intensity (a) 
Faint zone: 
Less intense than CA zone intensity (a) but equal to or more 
intense than CA zone intensity (b) 
Very faint zone: 
Less intense than CA zone intensity (b) 
 
 
               
              R           R¼ 
           
 
                                        4-fold dilution 
R: Reference solution 
R¼: 4-fold diluted reference solution 
 
Figure 7. Visual intensity description according to the general chapter 2.8.25 of the 




Figure 7. Visual intensity description according to the general chapter 2.8.25 of the 




Figure 8. Proposal of description for the identification of acacia and acacia 
spray/roller dried by HPTLC using the method developed as described in the present 
chapter (intensity marker: galactose). R: reference solution (a), R¼: 4-fold diluted 
reference solution (a). 
 
 Together with the implementation of the general chapter 2.8.25, the 9
th
 
edition of the Ph. Eur. has introduced another significant improvement for 
the interpretation of the chromatograms, the publication of colour pictures 
of the chromatograms. They are not published in the Pharmacopeia itself 
but in the Knowledge database. They are not mandatory, but given only as 
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information. Pictures include type chromatograms, helping with the 
identification of the zones referred to in the description table of the 
chromatograms of the individual monographs, as well as pictures of several 
batches of the herbal drug or preparation to show natural variability. Figure 8 
shows an example of a type chromatogram and proposal of description of 
results according to the new chapter 2.8.25 of the Ph. Eur. for acacia and 
acacia spray/roller dried. Other Pharmacopoeias and Compendia [13-19] also 
started to publish pictures of the chromatograms. 
 
4. Development of an HPTLC method 
 
 The routine chromatographic identification of polysaccharide rich herbal 
drugs and preparations thereof, such as gums, mucilages and starches is based 
on the TLC analysis of the monosaccharides released by hydrolysis. In the 
8
th
 edition of the Ph. Eu. [20], TLC identification was described in a limited 
number of the monographs related to this class of compounds and HPTLC was 
not described in any of them. In addition, the sample preparation was tedious 
and applied different conditions of hydrolysis. The TLC methods had also 
different mobile phases and three different detection reagents. With the aim of 
setting up an improved and harmonised general method for identification of 
this type of herbal drugs and preparations, suitable for routine quality control, 
an HPTLC method was developed and adapted to the requirements of the new 
Ph. Eur. chapter 2.8.25, published in the 9
th
 edition [1]. 
 In the next paragraphs, the parameters studied and the conclusions 
obtained will be summarized [21]. 
 For the preparation of the test solution, the hydrolysis at 100 ºC                 
(1h, oven) and 120 ºC (1 h, oven or autoclave), using different 
concentrations of trifluoroacetic acid (TFA) (100 g/L and 230 g/L) were 
tested. After the hydrolysis, the need of evaporating the acid (which is time 
consuming) was tested, as well as the suitability of the use of methanol 
instead of water as final solvent. TFA at 100 g/L, 120 ºC, during 1 h, were 
the conditions selected for hydrolysis, and the subsequent treatment was 
considerably shortened by avoiding evaporation of the acid. Methanol as 
final solvent was considered suitable. 
 The starting point for the chromatographic separation were the              
TLC methods already described in the Ph. Eur. [20] for ispaghula (seed and 
husk) guar and guar galactomannan. The separation was performed using 
one development with acetonitrile, water (85:15 v/v), in a saturated chamber. 
The main problem of this system was the relatively low RFs and a limited 
separation of the monosaccharides. With the aim of improving the 
separation, other proportions of this binary solvent system were tested,                
as well as the addition of different proportions of a third solvent, either 
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acetone or 1-propanol. Saturation with different solvents as well as the use of 
an unsaturated chamber were also investigated. And, finally, the suitability 
of multiple developments was verified. An optimised separation was 
obtained using HPTLC silica gel 60 F254 plates conditioned to a relative 
humidity of 33%, and double development with acetonitrile, water (85:15 
v/v) in an unsaturated chamber. 
 For the detection, four derivatisation reagents were tested, and 
diphenylamine - aniline - phosphoric acid reagent was selected, with 
observation under white light. 
 Three pairs of reference substances were tested as candidates for the 
system suitability test (SST). Galactose and glucose were considered the 
most suitable pair as SST for the qualification of the plate. 
 Finally, as intensity marker, a monosaccharide was individually chosen 
for each herbal drug or herbal preparation. 
 A description to which the chromatogram has to comply was prepared 
for each herbal drug/preparation, together with the type chromatogram, 
according to the general chapter 2.8.25 of the Ph. Eur. A proposal for acacia 
and acacia spray/roller dried is shown in Fig. 8. The application of the 
method to different herbal drugs and preparations is shown in Fig. 9. 
 






Figure 9. HPTLC chromatograms of several  
19-20. Guar   
21. Carob gum 
22.-23. Gal, Xyl (23 diluted) 
24-27. Irish moss 
28. Carrageenan 
29-30. Ispaghula husk 
31-40. Ispaghula seed  
41-42. Glc, Man (42 diluted) 
43-45. Xanthan gum   
46-47. Rice starch   
48-49. Maize starch   
50. Wheat starch   
51. Potato starch  
1. SST 
2-3. Gal, Glc, Ara, Xyl, Rha  
(3 diluted) 
4. Acacia, roller-dried 
5-6. Acacia   
7-8. Acacia, spray-dried 
9. Acacia   
10-11. Agar   
12. Tragacanth 
13-14. Gal, Man, Ara, Xyl  
(14 diluted) 
15. Ispaghula seed   
16-18. Psyllium seed   
 
 
Figure 9. HPTLC chromatograms of several polysaccharide containing herbal drugs 
and preparations, using the method developed as described in the present chapter. 
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5. Comprehensive HPTLC fingerprinting 
 
 HPTLC is nowadays adopted by the major pharmacopoeias of the world 
for analysis of herbal drugs and preparations. The current use is generally 
limited to the visual observation of the fingerprints for identification and 
detection of adulterations and falsifications. However, standardisation of 
methodology offers the necessary reproducibility that allows a deeper 
exploitation of this technique in the field of herbal products. Indeed, the 
HPTLC fingerprint, as an electronic image of the chromatogram, when 
generated by a standardized methodology under use of suitable instruments 
and software, and qualified by a SST, can also provide quantitative 
information based on the intensity of zones [22]. This information can be 
used for performing limit tests (e.g. for adulterants), determining content of 
active constituents or markers, or development of other quality parameters 
that need quantitative data. This quantitative information can be accessed by 
converting HPTLC fingerprints (electronic images) into peak profiles from 
images (PPI) by calculating the luminance from the average of RGB pixels 
of each line of the track and then plotting it against the RF values. Figure 10 
shows this process. The height of the peak in luminance is used as measure 
of intensity and is compared with the corresponding peak of reference 
material. This comparison is far more objective than the simple visual 




Figure 10. Transformation of the electronic image of the HPTLC chromatogram into 
the corresponding peak profile from image (PPI). 
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 Based on that, the concept of “comprehensive HPTLC fingerprinting” 
has been developed [7]: HPTLC fingerprints used for identification, are 
converted into PPI and used for obtaining information on purity and/or 
strength/content of the herbal drug or preparation analysed. A single analysis 
by HPTLC gives comprehensive information on quality and allows the 
simplification of the quality control process.  
 The proof of concept has been illustrated in the case of the quality 
control of the root of Korean angelica (Angelica gigas Nakai), known as 
dang gui and commonly used in the Republic of Korea [7]. It contains 
decursin and decursinol angelate, which are used as quality markers and a 
minimum content is required. Two other species of Angelica, Japanese 
angelica (A. acultiloba (Siebold & Zucc.) Kitag) and Chinese angelica                     
(A. sinensis (Oliv.) Diels), also known as dang gui in their respective 
countries of origin, can be considered adulterants when mixed with the 
former. However, the roots of these two species contain Z-ligustilide, which 
is not present in the root of A. gigas. Comprehensive HPTLC fingerprinting 
of this herbal drug, means than after a single analysis, it is possible to 
retrieve the following information: 
 
- Identity, based on the visual observation of the fingerprint. 
- Distinction from the roots of other 27 Angelica taxa and related 
Apiaceae species, also based on the visual observation of the fingerprint. 
- Discrimination of roots of A. gigas adulterated with the roots of                      
A. sinensis or A. acutiloba, based on the PPI analysis of the presence of 
Z-ligustilide. A 5% of adulterant or even less can be clearly detected. 
- Compliance to an established minimum content of the sum of decursin 
plus decursinol angelate, based on the PPI analysis of the peak that is 
compared with the corresponding peak of the reference material. 
 
 Another example in which the use of comprehensive HPTLC 
fingerprinting can reduce the number of analyses needed for quality control 
is the refined dry extract of ginkgo leaf (Ginkgo biloba L.) [23]. The USP 
monograph [13] prescribes an HPTLC identification looking at the 
fingerprint of flavonoids, and an HPLC assay of flavonoids performed on the 
aglycons (quercetin, kaempferol and isorhamnetin) released after hydrolysis. 
The flavonoid content required is 22-27%. The extract can be adulterated 
with pure flavonoids (e.g. quercetin and rutin) or other herbal extracts rich in 
flavonoid glycosides releasing quercetin by hydrolysis. The objective of the 
adulteration is to give the same flavonoid content using less ginkgo leaf 
extract. For this reason, the USP includes an HPLC limit test for rutin and 
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quercetin. Comprehensive HPTLC fingerprinting applied to ginkgo products 
is able to check, after a single analysis: 
 
- Identity of the extract contained in the product, by visual evaluation of 
the fingerprint.  
- Adulterations with quercetin and/or rutin rich materials and the nature of 
the adulterant, also by visual evaluation. Most common adulterants can 
be detected: the extracts of sophora fruit or flower bud (Styphnolobium 
japonicum (L.) Schott, syn: Sophora japonicum L.), and of buckwheat 
herb (Fagopyrum sp Moench), as well as pure rutin or quercetin. 
- Compliance to the USP limit test for quercetin and rutin, using the PPIs 
obtained from the fingerprints acquired from different detections on the 
same plate. Results from the HPTLC analysis show a very good 
correlation with those obtained by HPLC according to the USP. 
Consequently, the HPLC limit test prescribed by the USP could be 
avoided by means of a deeper exploitation of the fingerprints obtained in 
the HPTLC analysis for identification. 
 
6. Conclusions and future prospects 
 
 HPTLC is a simple, visual and pragmatic technique, capable of 
delivering reliable and reproducible results, based on standardized 
methodology and the use of SST for plate qualification. The improvements 
introduced in the Pharmacopoeias, especially in the Ph. Eur. and the USP, 
together with the instrumentation and software allowing to record 
normalized electronic images of the chromatograms (fingerprints) and their 
transformation into peak profiles (PPI), open the door to retrieve quantitative 
information from the analysis performed for identification. Based on that, 
the concept of comprehensive HPTLC fingerprinting has been introduced. It 
allows simplification of quality control processes for herbal 
drug/preparations/products, because from a single HPTLC analysis, 
information on identity, purity and content can be obtained. 
 Additionally, HPTLC results generated on different plates can now be 
compared based on the electronic images of the fingerprint. Images can be 
stored in an electronic atlas or even in a cloud, which can be accessed by 
different labs, enabling global exchange and collaboration. 
 Herbal drugs and herbal preparations have a high chemical complexity 
and they are considered the active pharmaceutical ingredients in their 
entirety [10]. The traditional approach of assaying a selected marker, that 
often represents only 0.02 to 5% of the total composition, has a limited 
significance for the level of quality and it is under discussion. A more 
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holistic approach, considering a wider range of constituents would be 
suitable. In this context, the HPTLC chromatographic profiling of herbal 
drugs/preparations/products appears as an essential tool to stablish its quality 
[24,25]. Probably, chemometrics will help on that, but how it will develop is 
still unknown, because it is not only depending on the technical capacities, 
but on how to establish official criteria of acceptance that can be 
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